The QualityStocks Daily Friday, November 4th, 2022

Today's Top 3 Investment Newsletters

QualityStocks(OCFT) $0.9128 +45.51%

The Stock Dork(SNTG) $4.0900 +34.54%

FreeRealTime(WLDN) $16.7700 +29.30%

The QualityStocks Daily Stock List

Puma Biotechnology (PBYI)

The Street, StocksEarning, StreetInsider, InvestorPlace, MarketBeat, Schaeffer's, MarketClub Analysis, Money Morning, StockMarketWatch, Real Pennies,, StreetAuthority Daily, BUYINS.NET, Kiplinger Today, QualityStocks, The Weekly Options Trader, Daily Trade Alert, Zacks, Barchart, TopStockAnalysts, Weekly Wizards, TraderPower, CustomerService, Profit Confidential, Trades Of The Day, CRWEFinance, CrashTrade, FreeRealTime, CRWEPicks, DrStockPick, CRWEWallStreet, BestOtc, Hit and Run Candle Sticks, Investing Futures, BestChartNow, Investopedia, InvestorsUnderground, Market Intelligence Center, Market Intelligence Center Alert, PennyToBuck, Rick Saddler, Schaeffer’s, StockEarnings, StockHotTips, Stocks To Watch, Streetwise Reports, SwingTradeOnline, The Online Investor, Wealth Insider Alert, WStreet Market Commentary and PennyOmega reported earlier on Puma Biotechnology (PBYI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Puma Biotechnology Inc. (NASDAQ: PBYI) is a biopharmaceutical firm that is engaged in developing and commercializing products that improve cancer care.

The firm has its headquarters in Los Angeles, California and was incorporated in 2010, on September 15th by Alan H. Auerbach. It operates as part of the pharmaceutical and medicine manufacturing industry and serves consumers around the globe. The firm has three companies in its corporate family.

The company operates through its subsidiaries, i.e. Puma Biotechnology B.V. and Puma Biotechnology Ltd. It is focused on in-licensing drug formulations which have already concluded or are undergoing initial clinical testing for the treatment of cancer. The company plans to further develop these formulations for commercial use. It is party to sub-license agreements with Bixink Therapeutics Co. Ltd, Pierre Fabre Medicament SAS, Knight Therapeutics Inc., Pint Pharma International S.A., Canbridge Biomed Ltd and Specialized Therapeutics Asia Pte Limited. It is also party to a license agreement with Pfizer Inc.

The enterprise’s product pipeline comprises of a formulation dubbed PB272, which has been developed for HER2 mutation-positive solid tumors. This formulation is also indicated for the adjuvant treatment of adults with early stage HER2-amplified/overexpressed breast cancer. In addition to this, the formulation is also indicated for use in combination with capecitabine for the treatment of metastatic or advanced HER2-positive breast cancer.

The firm’s PB272 formulation recently received regulatory approval in South Korea. The enterprise is now planning to meet with the FDA to discuss accelerated approval for the formulation in the treatment of HER2-mutated hormone receptor positive breast cancer. The approval of this formulation in the U.S. would not only offer support to patients battling breast cancer but also bring in more investments into the firm, which would be good for its growth.

Puma Biotechnology (PBYI), closed Friday's trading session at $2.71, up 26.6355%, on 495,769 volume. The average volume for the last 3 months is 7.538M and the stock's 52-week low/high is $1.60/$6.76.

OneConnect Financial Technology (OCFT)

StreetInsider, QualityStocks, InvestorPlace, Wealth Insider Alert, MarketBeat, Zacks and FreeRealTime reported earlier on OneConnect Financial Technology (OCFT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

OneConnect Financial Technology Co. Ltd (NYSE: OCFT) (HKG: 6638) is a holding firm that is engaged in the provision of online information and operating support services and cloud platform-based fintech solutions for financial institutions.

The firm has its headquarters in Shenzhen, China and was incorporated in December 2015. It operates as part of the software-applications industry, under the technology sector. The firm serves consumers in the People’s Republic of China.

The company is party to a strategic agreement with the Hainan Local Financial Supervision Administration, which involves the development of smear financial and supervision services in the Hainan Province. It operates through the Virtual bank business and the Technology solutions segments. The latter segment is the company’s key revenue driver.

The enterprise provides digital commercial banking, digital retail banking, digital life insurance and auto insurance and artificial intelligence customer services, as well as risk management, sales management operation support services. It also operates a customer-centric solution known as the gamma core banking system; and a digitalized management platform which provides digital infrastructure to financial institutions for the management of different aspects of their business, including liability and asset management, comprehensive risk and smart operation data as well as office and personnel management.

The company recently announced its latest financial results, which show increases in its revenues. It remains focused on implementing its second-stage strategy, which will help fulfill its mission and further solidify its position in the market. This will, in turn, influence revenues and investments into the company positively.

OneConnect Financial Technology (OCFT), closed Friday's trading session at $0.9128, up 45.5125%, on 7,538,215 volume. The average volume for the last 3 months is 20,732 and the stock's 52-week low/high is $0.4727/$3.12.

Cogna Educacao (COGNY)

QualityStocks, MarketBeat and InvestorPlace reported earlier on Cogna Educacao (COGNY), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Cogna Educacao SA (OTC: COGNY) (FRA: KE0A) (BVMF: COGN3) is a private educational organization focused on providing educational services.

The firm has its headquarters in Belo Horizonte, Brazil and was incorporated in 1966, on April 11th by Júlio Fernando Cabizuca, Evando José Neiva, Walfrido Silvino dos Mares Guia, Gabriel Mário Rodrigues and Altamiro Belo Galindo. Prior to its name change, the firm was known as Kroton Educacional SA. It operates as part of the education and training services industry, under the consumer defensive sector. The firm serves consumers in Brazil and around the globe.

The enterprise operates through the In-Class Higher Education, Distance Learning Higher Education, and Basic Education segments. It publishes, sells, and distributes textbooks, support materials, and workbooks with educational, literary, and informative content and teaching systems; provides in-class and distance-learning higher education, and undergraduate and graduate courses; and educational solutions for professional and higher education, and other supplementary activities, such as developing education technology with management and other education services. The enterprise develops software for adaptive teaching and academic management optimization; offers technical and preparatory courses for civil service examinations and Brazilian Bar Association; and K-12 education, pre-college preparatory, language courses for children and teenagers; and provides management of child, primary, and secondary education activities. Its services include on-campus undergraduate and graduate programs and graduate programs.

The company remains focused on occupying a larger share in the educational market, which will enable it to reach more consumers and generate additional revenues. This is in addition to open it up to more growth opportunities and bolstering its overall growth.

Cogna Educacao (COGNY), closed Friday's trading session at $0.5991, up 1.5768%, on 20,732 volume. The average volume for the last 3 months is 527,011 and the stock's 52-week low/high is $0.3315/$0.642.

Membership Collective Group (MCG)

MarketBeat and QualityStocks reported earlier on Membership Collective Group (MCG), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Membership Collective Group Inc. (NYSE: MCG) (FRA: 75Z) is a holding firm that provides a global membership platform of physical and digital spaces.

The firm has its headquarters in New York, New York and was incorporated in 1995 by Nicholas Keith Arthur Jones. It operates as part of the lodging industry, under the consumer cyclical sector. The firm serves consumers around the globe.

The company operates through the following segments: the United Kingdom, Europe, North America and Rest of the World, and Soho House Design. It is the only company to have scaled a private membership with an international presence. The company connects a vibrant, diverse group of members from across the world. Its members use the platform to work, socialize, connect, create and flourish all over the world.

The enterprise members engage with the firm via its international portfolio, which comprises of about nine Soho Works, 33 Soho Houses, Scorpios Beach Club in Mykonos, The Ned in London, Soho Home, its interiors and lifestyle retail brand, and its digital channels. A Soho House membership offers access to a network of Houses across North America, the United Kingdom, Europe, and Asia. It hosts physical and digital member events worldwide spanning film, fashion, art, food and drink, well-being, work, and music.

The firm’s latest financial results show significant increases in its revenues, driven by continued strong membership growth. It remains focused on meeting its membership targets and enhancing membership value, which will create shareholder value and positively influence the firm’s overall growth.

Membership Collective Group (MCG), closed Friday's trading session at $4.82, up 4.7826%, on 527,011 volume. The average volume for the last 3 months is 15 and the stock's 52-week low/high is $3.14/$14.00.

China Gold International Resources (JINFF)

We reported earlier on China Gold International Resources (JINFF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

China Gold International Resources Corp Ltd (OTC: JINFF) (TSE: CGG) (FRA: J13) (HKG: 2099) is a gold and base metal mining firm that is focused on acquiring, exploring for, developing and mining mineral properties.

The firm has its headquarters in Vancouver, Canada and was incorporated in 2000, May 31st. Prior to its name change, the firm was known as Jinshan Gold Mines Inc. It operates as part of the other precious metals and mining industry, under the basic materials sector. The firm serves consumers in the People’s Republic of China.

The company primarily operates two mines in China: the CSH Mine which produces gold and the Jiama Mine which produces gold and copper. It generates most of its revenues from gold mining, with a considerable portion of sales resulting from the production of copper. China National Gold Corporation, a state-owned firm registered in Beijing, is a significant shareholder of the company.

The enterprise holds 96.5% interest in the Chang Shan Hao (CSH) gold mine covering an area of 36 square kilometers in the western part of Inner Mongolia, northern China. It also holds 100% interest in the Jiama project, a copper-gold polymetallic mine that hosts copper, gold, molybdenum, silver, lead, and zinc metals located approximately 60 kilometers east of Lhasa City along the Sichuan-Tibet Highway, in Metrokongka County, Tibet.

The firm is focused on growing sustainably and increasing its copper and gold production, which will not only bring in additional revenues and investments into the firm, but also help create shareholder value.

China Gold International Resources (JINFF), closed Friday's trading session at $2.3413, even for the day, on 15 volume. The average volume for the last 3 months is 778,908 and the stock's 52-week low/high is $2.30/$4.17.

Pagaya Technologies (PGY)

MarketClub Analysis, QualityStocks, MarketBeat, Schaeffer's and INO Market Report reported earlier on Pagaya Technologies (PGY), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Pagaya Technologies Ltd (NASDAQ: PGY) is a financial technology firm that is engaged in the provision of software solutions.

The firm has its headquarters in Tel Aviv, Israel and was incorporated in 2016. It operates as part of the software-infrastructure industry, under the technology sector. The firm serves clients around the globe, with a focus on consumers in the United States.

The company is focused on helping its partners grow faster as well as smarter by creating new lending opportunities for its partners. It was built to provide a comprehensive solution to enable the credit industry to deliver a positive experience to customers while simultaneously improving the broader credit ecosystem. The company’s proprietary API seamlessly integrates into its next-gen infrastructure network of partners to deliver a premium customer user experience and greater access to credit.

The enterprise is primarily engaged in the financial technology (FinTech) industry. It is involved in the development and implementation of proprietary artificial intelligence technology and related software solutions to assist partners to originate loans and other assets. Thanks to its solutions, its customers gain credit approvals without undue risk. Its partners include high-growth financial technology companies, incumbent financial institutions, auto finance providers, and brokers.

The firm recently announced its latest financial and operational results, which show strong network volume and increases in its revenues as well as income. It is committed to growing its revenues and delivering consistent growth through macro cycles, which will help generate value for its shareholders.

Pagaya Technologies (PGY), closed Friday's trading session at $1.26, off by 5.2632%, on 778,908 volume. The average volume for the last 3 months is 14,835 and the stock's 52-week low/high is $1.15/$34.50.

S4 Capital (SCPPF)

MarketBeat and QualityStocks reported earlier on S4 Capital (SCPPF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

S4 Capital PLC (OTC: SCPFF) (LON: SFOR) (FRA: 9S4) is a digital advertising and marketing services firm that is engaged in the provision of digital advertising and marketing services.

The firm has its headquarters in London, the United Kingdom and was incorporated in 2016, on November 14th. Prior to its name change, the firm was known as Derriston Capital. It operates as part of the advertising agencies industry, under the communication services sector. The firm serves consumers around the globe, with a primary focus on Europe, the Americas, the Middle East, Africa and the Asia Pacific.

The company integrates businesses in three practice areas: First-Party Data, Content, and Programmatic. It operates through the data and digital media as well as content practice segments. The Data and Digital Media segment encompasses full-service campaign management analytics, platform and systems integration and transition, creative production and ad serving, and training and education. On the other hand, the Content Practice segment includes creative content, campaigns, and assets for paid, social, and earned media from digital applications and platforms to brand activations that aim to convert consumers at every possible touchpoint.

The enterprise provides content and campaigns for social media as well as brand activations. It also provides digital transformation services in delivering digital product design, engineering services, and delivery services.

The firm, which recently announced its latest financial results, is focused on leasing new spaces, expanding its major client relationships and achieving its objectives. This will not only bring in additional revenues and open it up to new growth opportunities but also create shareholder value.

S4 Capital (SCPPF), closed Friday's trading session at $2.01, even for the day, on 14,835 volume. The average volume for the last 3 months is 186,226 and the stock's 52-week low/high is $1.31/$9.945.

SurgePays Inc. (SURG)

Wall Street Resources, SmarTrend Newsletters, SmallCapVoice, MoneyTV, StockRockandRoll, PennyStockLocks, StreetInsider, Penny Stock 101, QualityStocks, Market Report, Penny Stock General, OTCPicks, Greenbackers, The Street, Shiznit Stocks, StockOodles, InvestorPlace, StockHotTips, Stockhouse, DrStockPick, MassiveStockProfits, CRWEPicks, PennyOmega, Zacks, CRWEFinance, PennyToBuck, BestOtc, CRWEWallStreet, ChartAdvisor, Wall Street Daily, Barchart, MarketBeat, OTCtipReporter, Small Cap Firm, Street Insider, Penny Stock 112, Penny Stock 118, AllPennyStocks, PennyStockScholar, PennyTrader, StockOnion, Real Pennies and Mega Stock Alerts reported earlier on SurgePays Inc. (SURG), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

SurgePays Inc. (NASDAQ: SURG), a technology and telecommunications company focused on the underbanked and underserved, has started the process to apply to dual list its shares of common stock on Upstream, the revolutionary trading app for digital securities and NFTs; the app is powered by Horizon Fintex and MERJ Exchange Limited. According to the announcement, the company anticipates the Upstream dual listing will provide access to a global, digital-first investor base that can trade using USDC digital currency as well as credit, debit, PayPal and USD. This wider reach could unlock liquidity and enhance price discovery while also offering international investors the opportunity to invest in a NASDAQ-listed company. The announcement noted that Upstream is a fully regulated global stock exchange that allows users to trade NFTs and invest in securities for IPOs, crowdfunded companies, and U.S. and international equities, as well as celebrity ventures. “We believe a dual listing on Upstream provides our company access to the global capital markets and the technology to reach countless potential new investors,” said SurgePays CEO and chair Brian Cox in the press release. “In addition, as an advocate of the underbanked and underserved, the Upstream platform opens up the world of digital assets to those without bank accounts, brokerage accounts or credit cards. We have an exciting story to tell and believe this listing provides an even greater audience to learn about our growth potential. I expect the relationship with Upstream to develop beyond the dual listing. We are planning to integrate a Web3 community-building strategy using Upstream’s carbon neutral, noncustodial Web3 platform to distribute digital coupons (incentive NFTs) for prepaid wireless and mobile broadband subscribers to redeem for discounts and other rewards at stores transacting on the SurgePays platform.”

To view the full press release, visit

About SurgePays Inc.

SurgePays is a technology and telecommunications company focused on the underbanked and underserved communities. SurgePhone Wireless provides mobile broadband to low-income consumers nationwide. SurgePays blockchain fintech platform utilizes a suite of financial and prepaid products to convert corner stores and bodegas into tech hubs for underbanked neighborhoods. For more information about the company, visit

SurgePays Inc. (SURG), closed Friday's trading session at $5.8, up 10.4762%, on 186,226 volume. The average volume for the last 3 months is 6,852 and the stock's 52-week low/high is $1.76/$7.30.

Bion Environmental Technologies Inc. (BNET)

QualityStocks, MarketBeat, Wall Street Resources, News, OTC Stock Review, TradersPro, TopPennyStockMovers and Stock Guru reported earlier on Bion Environmental Technologies Inc. (BNET), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Bion Environmental Technologies (OTCQB: BNET), a developer of advanced livestock waste treatment technology that dramatically reduces environmental impacts and recovers valuable resources, has broken ground on a small commercial-scale Gen3Tech facility that will be located near Fair Oaks, Indiana. According to the announcement, Bion expects building construction to be completed by Dec. 15, 2022, with waste processing equipment delivered by mid-January. The Gen3Tech platform’s successful operation at Fair Oaks will demonstrate its scalability and allow nitrogen recovery efficiencies to be optimized at scale. Bion will use operating data from the Fair Oaks facility to design its first full-scale commercial project and support certification requirements for various regulatory agencies to establish a USDA-certified sustainable brand. In addition, the facility will produce ammonium bicarbonate fertilizer for both commercial testing by potential joint venture partners and university growth trials.

“A couple key takeaways: first, this is the final engineering step before we are ready to launch full-scale commercial projects. While we expect normal engineering challenges associated with scaling up, we don’t anticipate any major ones because most of this equipment is already in use at larger scale,” said Craig Scott, Bion’s director of communications. “Second, and most important: we are NOT another digester company that will power a couple thousand homes from cow manure. Bion’s key differentiator is the comprehensive solution we bring to all the environmental problems associated with livestock waste – air, water and soil – not just methane and climate change. That comprehensive solution also generates multiple revenue streams, not just one. And while climate impacts need to be addressed, we believe the more pressing problem is the industry’s direct impacts to water quality and human health. In our opinion, developing anaerobic digester projects to extract renewable energy, without addressing ammonia/ nutrient control, is a ticking timebomb that will create greater problems in the future.”

To view the full press release, visit

About Bion Environmental Technologies Inc.

Bion’s patented third generation technology (“Gen3Tech”) was designed to largely mitigate the environmental impacts of large-scale livestock production and deliver a USDA-certified sustainable product to the consumer. The platform simultaneously recovers high-value environmentally friendly fertilizer coproducts and renewable energy that increase revenues. Bion’s Gen3Tech platform can create a pathway to economic and environmental sustainability with “win-win” benefits for a premium sector of the $175 billion U.S. livestock industry and the consumer. For more information, see Bion’s website at

Bion Environmental Technologies Inc. (BNET), closed Friday's trading session at $1.1675, up 6.1364%, on 6,852 volume. The average volume for the last 3 months is 381,458 and the stock's 52-week low/high is $0.80/$1.75.

Seelos Therapeutics Inc. (SEEL)

MarketBeat, StockMarketWatch, MarketClub Analysis, QualityStocks, TradersPro, Schaeffer's, BUYINS.NET, Trades Of The Day and INO Market Report reported earlier on Seelos Therapeutics Inc. (SEEL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

The National Institutes of Health has awarded a grant to researchers at Johns Hopkins University to find out whether psychedelics can help smokers quit smoking. This is the first time in decades that a federal grant has been awarded to carry out research on a psychedelic as a potential treatment.

We have seen interest in psychedelics grow significantly these last few years, especially as more studies find that these drugs may be useful in the treatment of a range of mental health disorders, including post-traumatic stress disorder, depression and addiction. For instance, research published a few months ago found that psilocybin may help decrease alcohol cravings.

The NIH study, a randomized controlled trial that will look into whether psilocybin can help individuals quit smoking tobacco, is expected to begin later this year. Psilocybin is the primary active compound found in hallucinogenic mushrooms.

The trial will involve scientists at Hopkins in collaboration with researchers at the University of Alabama at Birmingham and NYU Langone Health. The randomized controlled trial will be led by psychedelic researcher Matthew Johnson of Johns Hopkins Medicine.

The trial’s objective is to examine the effects psilocybin will have on smoking cessation. At the moment, individuals who want to quit may find it hard to access effective treatments. Data from the CDC shows that quitting smoking is very hard, with less than 1 in 10 smokers who try to do so succeeding annually.

Johnson explains that existing treatments all have room for improvement, especially since none of the drugs helps most individuals in the long-term.

The NIH-funded trial will include roughly 66 participants who will be divided into two groups. Participants in one group will receive two doses of psilocybin while those in the other group will receive two doses of niacin, a type of B vitamin. After this, each participant will undergo talk therapy with licensed therapists.

The team of Johns Hopkins researchers is also involved in another open-label trial examining how effective psilocybin is in helping quit smoking, in comparison to nicotine patches.

University of California- San Francisco’s Dr. Joshua Woolley of the psychiatry department states that the lack of support for research into psychedelics in the past from the NIH has been a major obstacle in the field. Dell Medical School’s Dr. Charles Nemeroff adds that the NIH’s interest in such studies is great as it affords researchers the essential funding needed to carry out controlled studies. Neither Nemeroff and Woolley are not involved with the new study.

Plenty of R&D programs are ongoing at enterprises such as Seelos Therapeutics Inc. (NASDAQ: SEEL) that are aimed at formulating medicines from psychedelic compounds. As this research bears fruit, patients suffering from different indications could have these novel treatments as viable options.

Seelos Therapeutics Inc. (SEEL), closed Friday's trading session at $0.8774, off by 2.5111%, on 381,458 volume. The average volume for the last 3 months is 4.429M and the stock's 52-week low/high is $0.4803/$2.32.

Fisker Inc. (FSR)

InvestorPlace, Schaeffer's, StocksEarning, MarketClub Analysis, MarketBeat, Kiplinger Today, The Street, QualityStocks, The Online Investor, Trades Of The Day, Daily Trade Alert, TradersPro, Early Bird, StreetInsider, TipRanks, wyatt research newsletter, Cabot Wealth, InvestorsUnderground and CNBC Breaking News reported earlier on Fisker Inc. (FSR), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

The race for who dominates the electric vehicle industry has barely started as engineers at different EV manufacturing facilities battle to boost EV range as well as the speed at which the batteries can be charged, among other issues of electric vehicles. However, the front trunk or “frunk,” is proving to be a divisive factor, with some complaining about the features while others are reporting it could popularize electric vehicles in ways no manufacturer had imagined possible.

For starters, there seems to be no agreement regarding the necessity of a frunk on an electric vehicle other than using as extra storage space where an engine should have been. Looking through the models of EVs on American roads shows that approximately one-third of them have typical frunks, with another third having extra-large frunks and the remaining third leaving them out altogether.

Ford’s F-150 Lightning pickup boasts of having the largest frunk among all EVs while the Model Y from Tesla comes with a 4.1 cubic-foot frunk. These are examples of vehicle makers who are taking the frunk seriously and are looking to market their EVs by singing the praises of what one can do with such massive storage space, space that was freed when the engine was made obsolete and batteries were lined up on the bed of the vehicle.

Other companies, such as Mercedes Benz, see no reason to have a frunk when the trunk is sufficient to carry what a motorist needs. As such, its EQS sedan, as well as the BMW i4 sedan, doesn’t sport any frunk.

Other companies fall somewhere along this continuum, but what is interesting is how the frunks have become a powerful marketing force for EVs. On Snapchat, there is a #FrunkPuppy challenge where motorists share and gloat over photos of their dogs lounging inside the frunk of their electric vehicles. Ford even put out a promotional video actually showing that the frunk on the F-150 Lightning can be a mobile sushi bar — or those not so inclined toward raw seafood can comfortably put a thousand chicken wings on ice inside the frunk.

These trends gathering steam on social media are likely to give electric vehicle makers plenty of milage and free marketing because they get ordinary people talking about different electric vehicle models, which can normalize EVs and drive sales. It remains to be seen how manufacturers such as Fisker Inc. (NYSE: FSR) will tap into this new craze surrounding frunks in order to tweak their EV model plans or swim against the tide and appeal to those who want a no-frills method of locomotion. Either way, the EV industry wins.

Fisker Inc. (FSR), closed Friday's trading session at $7.5, off by 4.0921%, on 4,429,004 volume. The average volume for the last 3 months is 720,616 and the stock's 52-week low/high is $6.41/$23.75.

Arch Resource Partners L.P. (ARLP)

The Online Investor, Zacks, TradersPro, QualityStocks, The Street, MarketBeat,, MarketClub Analysis, InvestorPlace, TopStockAnalysts, Dividend Opportunities, TheStockAdvisor, The Wealth Report, The Motley Fool, Money Morning, StreetAuthority Daily, Market Intelligence Center Alert, BUYINS.NET, Investing Daily, Daily Wealth, Daily Trade Alert, Rick Saddler, TraderPower, SmarTrend Newsletters, The Growth Stock Wire, Wealth Insider Alert, TheOptionSpecialist, TheStockAdvisors, Trading Concepts, Daily Markets, Trades Of The Day, Eagle Financial Publications, Early Bird, FNNO Newsletters, Greenbackers, Insider Wealth Alert,, Investor Update, Short Term Wealth, Top Pros' Top Picks, Leeb's Market Forecast, TheTradingReport, TheStreet Offers, Money and Markets, StreetInsider and Investment U reported earlier on Arch Resource Partners L.P. (ARLP), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

The restrictions imposed in China to help contain the spread of the coronavirus are pushing up the price of coal and constraining the fuel’s supply. Coal traders show that spot prices for 5,500kcal thermal coal had increased by 9% in November, hitting a seven-month high of 1,650 yuan per ton.

Data from the National Health Commission shows that top coal-producing regions in the country have recorded hundreds of coronavirus cases, which has disrupted coal trade. The introduction of strict measures has even made it hard for some mines to ship the fuel out, which has caused production to stall. This comes just a few weeks before demand in the country increases as more people switch to using coal-fired heating systems for the winter.

China is the largest consumer of coal and relies on this fuel to heat homes, especially in the northern region. The East Asian nation is determined to ensure that it has adequate suppliers after shortages in 2021 caused power outages. The measures imposed include special licenses for lorries to enter mines. Drivers are also not permitted to leave their cabs during the shipment journeys, which usually cover thousands of kilometers.

Authorities also ordered residents in Zhungeer county to stay home after one coronavirus case was reported at a mine. This county contributes about 27% of coal produced in Inner Mongolia. One coal trader based in Zhungeer stated that mines had been forced to reduce their operations or even shut down if they couldn’t find lorries to transport their coal.

Mines have been shutting down for a while now, with two mines in the city of Wuhan suspending production about a fortnight ago.

Zhou Jie, a CCTD analyst, states that the impact of reduced coal production has slightly been offset by the fact that utilities haven’t yet increased their winter purchases. Data from CCTD also shows that the daily use of coal at major power plants along the coastal region has also dropped to less than 1.8 million tons, from its previous use of more than 2 million tons.

Data from another consultancy firm, Sxcoal, also shows that the number of vessels waiting to load coal from ports in China is roughly 80 a day. This figure is nearly 25% less than the figure recorded during the same period in 2021.

Traders are becoming more concerned that an outbreak may affect markets soon, especially once the heating season in northern China begins.

Such disruptions as seen in China are responsible for the additional demand that enterprises such as Arch Resource Partners L.P. (NASDAQ: ARLP) are seeing, resulting in rising coal prices around the world as supply is dwarfed by demand.

Arch Resource Partners L.P. (ARLP), closed Friday's trading session at $23.95, up 0.757257%, on 720,616 volume. The average volume for the last 3 months is 1.73M and the stock's 52-week low/high is $9.66/$27.63.

The QualityStocks Company Corner

Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR)

The QualityStocks Daily Newsletter would like to spotlight Energy Fuels Inc. (UUUU).

Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR),based in Lakewood, Colorado, is the country’s largest producer of uranium and the leading conventional producer of vanadium, both designated by the U.S. government as critical minerals.

As the leading U.S. diversified uranium miner, Energy Fuels’ uranium production portfolio stands apart in the world. Energy Fuels has more uranium production facilities, more production capacity, and more in-ground resources than any other company in the United States. In fact, the company’s assets have produced over one-third of all U.S. uranium over the past 15 years and is uniquely positioned to increase production to meet new demand.

Energy Fuels utilizes both conventional and in-situ recovery (“ISR”) technology to produce uranium from three strategic facilities:

  • White Mesa Mill in Utah (conventional) has a licensed capacity of over 8 million pounds of U3O8 per year. The highly strategic White Mesa Mill is the only conventional uranium mill in the country and is proximate to some of the largest and highest-grade uranium mines and projects in the U.S., including the Company’s Canyon mine, La Sal Complex, Henry Mountains Complex and Roca Honda Project. White Mesa Mill provides Energy Fuels with significant production scalability as uranium demand increases. The White Mesa Mill also has other diverse businesses, including vanadium, rare earth elements (REE’s), alternate feed materials recycling and land cleanup, all described below.
  • Nichols Ranch Plant (ISR) is located in the productive Powder River Basin district of Wyoming and has a total licensed capacity of 2 million pounds of U3O8 per year. Nichols Ranch has produced 1.2 million pounds of U3O8 since commissioning in 2014, and it has significant future expansion potential from 34 fully licensed wellfields containing significant in-ground uranium resources.
  • Alta Mesa Plant (ISR) is located on over 200,000 acres of private land in Texas. The fully licensed and constructed ISR project has a total operating capacity of 1.5 million pounds of uranium per year and produced nearly 5 million pounds of U3O8 between 2005 and 2013. This low-cost production facility is currently on standby, maintained in a state of readiness to respond to expected increases in demand.

In addition to being the largest uranium miner in the U.S., Energy Fuels’ overall portfolio also includes a pipeline of high-quality, large-scale exploration and development projects that are permitted or are in advanced stages of permitting, as well as an industry-leading U.S. NI 43-101 Mineral Resource portfolio.

FACTOID: Energy Fuels has led industry efforts over the past two-plus years to get the U.S. government to recognize the importance of domestically produced uranium, including the 2018 – 2019 Uranium Section 232, the ongoing Nuclear Fuel Working Group and the recently announced creation of the U.S. strategic uranium reserve. The U.S. is by far the largest consumer of uranium in the world, yet we import almost all of our requirements; Energy Fuels aims to change that.

Nuclear Market Potential

Multiple studies in top scientific journals have shown that nuclear power is cleanest and most economical way to produce reliable electricity as worldwide demand continues to soar. Nuclear power is presently the only available and affordable low-carbon power source that can meet both current and future baseload electricity demands while simultaneously reducing air pollution and mitigating climate change. U.S. nuclear power plants currently generate nearly 20% of the nation’s electricity overall and 55% of its carbon‐free electricity and even a modest increase in electricity demand would require significant new nuclear capacity by 2025. According to the World Nuclear Association (WNA), there are currently 441 operable reactors, with another 54 units under construction and 439 in various stages of planning; in addition, the WNA has identified a potentially massive supply/demand gap through 2040 of 1 billion pounds. These factors among others are expected to significantly drive increased demand for uranium.

Reasons Nuclear is Gaining Traction

  • Nuclear reactors emit no greenhouse gases during operation. Over their full lifetimes, they result in comparable emissions to renewable forms of energy such as wind and solar.
  • Unlike any other form of energy, the waste from nuclear energy is contained and managed securely. Used fuel is currently being safely stored for ultimate disposal or future reprocessing, and 96% of this waste can potentially be recycled.
  • Greater demand for clean electricity to power everything from homes to automobiles, reducing dependence on fossil fuels.

No. 1 U.S. Producer of Vanadium in 2019

Energy Fuels also produces vanadium as a byproduct of uranium production. Vanadium is designated a critical mineral, essential to the economic and national security of the United States. Energy Fuels was the largest producer of vanadium in the U.S. in 2019, and has significant high-grade, in-ground vanadium resources, as well as a separate high-purity vanadium production circuit at their White Mesa Mill, which is also the only conventional vanadium mill in the country. Crucial for use in the steel, aerospace, and chemical industries, vanadium plays a critical role in the production of high-strength and light-weight metallic alloys and demand is expected to increase across the globe.

Energy Fuels has several fully permitted and developed standby mines containing large quantities of high-grade vanadium, along with uranium, including:

  • La Sal Complex (Utah)
  • Whirlwind Mine (Colorado/Utah)
  • Rim Mine (Colorado)

Vanadium has also gained increased attention as a catalyst in next-generation high-capacity, “community-scale” batteries used for energy storage generated from renewable sources. Demand is only expected to grow as this market expands. With recent upgrades in its vanadium production operations, in 2019 Energy Fuels produced commercial levels of the highest purity (99.7%) vanadium in the mill’s history and can rapidly adjust production to meet volatile market conditions. Energy Fuels is one of the very few known avenues that provides investors access the vanadium market.

Rare Earth Element (REE) Production, Alternate Feed Material Recycling, and Land Cleanup

The White Mesa Mill also provides the company with diverse cashflow generating opportunities. Security of supply for Rare Earth Elements (REEs) supporting U.S. military and defense requirements is a major issue today. Energy Fuels has been approached by a number of entities, including the U.S. government, inquiring about the potential to process certain REEs at the mill. The White Mesa Mill is currently licensed to process certain REEs, including tantalum and niobium. And, early indications are that the mill can be utilized to produce several other REEs. The White Mesa Mill is also the only facility in North America licensed and capable of recycling alternate feed materials (AFMs). AFMs are essentially low-level waste materials that contain recoverable quantities of natural (or unenriched) uranium. The Company typically generates between $5 and $15 million per year from AFM recycling. Finally, Energy Fuels is seeking to become involved in the cleanup of legacy Cold War era uranium mines in the Four Corners region of the U.S., including on the Navajo Nation. The U.S. Environmental Protection Agency (EPA) has access to over $1.5 billion for the cleanup of just a fraction of the sites on the Navajo Nation. The White Mesa Mill is fully licensed to receive much of this material, we are one of the government’s lowest cost options, and we have the ability to recycle the material and produce usable uranium from it.

Management Team

Mark S. Chalmers, President and CEO
Mark S. Chalmers is the president and chief executive officer of Energy Fuels, a position he has held since Feb. 1, 2018, following his role as chief operating officer of Energy Fuels from July 1, 2016 – Jan. 31, 2018. From 2011 to 2015, Chalmers served as executive general manager of Production for Paladin Energy Ltd., a uranium producer with assets in Australia and Africa, including the Langer Heinrich and Kayelekera mines where, as head of operations, he oversaw sustained, significant increases in production while reducing operating costs. He also possesses extensive experience in in situ recovery (“ISR”) uranium production, including management of the Beverley Uranium Mine owned by General Atomics (Australia), and the Highland mine owned by Cameco Corporation (USA). Chalmers has also consulted to several of the largest players in the uranium supply sector, including BHP Billiton, Rio Tinto, and Marubeni, and until recently served as the chair of the Australian Uranium Council, a position he held for 10 years. Chalmers is a registered professional engineer and holds a Bachelor of Science in Mining Engineering from the University of Arizona.

W. Paul Goranson, COO
W. Paul Goranson is the chief operating officer for Energy Fuels. Goranson has 30 years of mining, processing and regulatory experience in the uranium extraction industry that includes both conventional and in-situ recovery (“ISR”) mining, and he is a registered professional engineer. Prior to the acquisition by Energy Fuels of Uranerz Energy Corporation, Goranson served as president, chief operating officer and director for Uranerz, where he was responsible for operations of the Nichols Ranch ISR Uranium Project. In addition to those duties, he also managed uranium marketing, regulatory and government affairs, exploration and land. Prior to joining Uranerz, Goranson served as president of Cameco Resources, where he led the operations at the Smith Ranch-Highland, Crow Butte and North Butte ISR uranium recovery facilities. Goranson also served as vice president of Mesteña Uranium LLC, and he has served in senior positions with Rio Algom Mining, (a subsidiary of BHP Billiton), and Uranium Resource Inc. Goranson has a Bachelor of Science in Natural Gas Engineering from Texas A&I University, and a Master of Science in Environmental Engineering from Texas A&M University-Kingsville.

David C. Frydenlund, CFO, General Counsel, Corporate Secretary
David C. Frydenlund is chief financial officer, general counsel, and corporate secretary of Energy Fuels. His responsibilities include oversight of all legal matters relating to the company’s activities. His expertise extends to NRC, EPA, state and federal regulatory and environmental laws and regulations. From 1997 to 2012, Frydenlund was vice president of regulatory affairs, general counsel and corporate secretary of Denison Mines Corp., and its predecessor International Uranium Corporation (“IUC”). He also served as a director of IUC from 1997 to 2006 and CFO of IUC from 2000 to 2005. From 1996 to 1997, Frydenlund was vice president of the Lundin Group of international public mining and oil and gas companies, and prior thereto was a partner with the Vancouver law firm of Ladner Downs (now Borden Ladner Gervais) where his practice focused on corporate, securities and international mining transactions law. Frydenlund holds a bachelor’s degree in business and economics from Simon Fraser University, a master’s degree in economics and finance from the University of Chicago and a law degree from the University of Toronto.

Curtis H. Moore, Vice President of Marketing and Corporate Development
Curtis H. Moore is the vice president of Marketing and Corporate Development for Energy Fuels. He oversees product marketing for Energy Fuels, and is closely involved in mergers & acquisitions, investor relations, public relations, and corporate legal. He has been with Energy Fuels for over 12 years, holding various roles of increasing responsibility. Prior to joining Energy Fuels, Moore worked in multi-family real estate development, government relations and public affairs, production homebuilding, and private law practice. Moore is a licensed attorney in the State of Colorado. He holds Juris Doctor and MBA degrees from the University of Colorado at Boulder, and a Bachelor of Arts dual degree in Economics-Government from Claremont McKenna College in Claremont, California.

Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) ("Energy Fuels" or the "Company") today reported its financial results for the quarter ended September 30, 2022. The Company's quarterly report on Form 10-Q has been filed with the U.S. Securities and Exchange Commission (" SEC ") and may be viewed on the Electronic Document Gathering and Retrieval System (" EDGAR ") at , on the System for Electronic Document Analysis and Retrieval (" SEDAR ") at , and on the Company's website at . Unless noted otherwise, all dollar amounts are in U.S. dollars.


At September 30, 2022 , the Company had a robust balance sheet with $122.3 million of working capital, including $77.1 million of cash and cash equivalents, $11.6 million of marketable securities, $27.3 million of inventory, and no short term (or long term) debt. At current commodity prices, the Company's product inventory has a value of $44.1 million .

During the quarter ended September 30, 2022 , the Company incurred a net loss of $9.3 million , which includes increases in development, permitting and land holding costs and selling, general and administration costs associated with the Company's efforts to enhance its business processes and operational readiness for the current and future growth and activity in our uranium and rare earth element (" REE ") operations.

With recent uranium market strength and having secured three long-term uranium contracts with major U.S. utilities earlier this year, the Company has hired over 20 new employees and is beginning to perform the work needed to recommence production at one or more of our mines and ISR facilities, starting as soon as 2023. Until such time when the Company has ramped back up to commercial uranium production, we can rely on our significant uranium inventories to fulfill our new contract requirements.

In June 2022 , the U.S. Department of Energy (" DOE ") issued aRequest for Proposals (" RFP ") to purchase uranium (" U 3 O 8 ") for the new U.S. Uranium Reserve Program. The DOE states that they expect to purchase up to 1 million pounds of U 3 O 8 inventory from up to four (4) qualified U.S. uranium producers with individual awards ranging from 100,000 pounds to 500,000 pounds. The uranium must be physically located at Honeywell's Metropolis Works conversion facility (the " U.S. Converter "). Energy Fuels believes it meets all qualifications to supply the Reserve, and the Company currently holds about 610,000 pounds of U 3 O 8 at theU.S. Converter. The Company has submitted a bid to sell U 3 O 8 to the Reserve, taking into consideration our long-term contract commitments and current and expected market conditions. There are no guarantees the DOE will purchase uranium from the Company under this RFP. Assuming the bid review process is not extended by DOE, the Company expects the DOE to issue the awards by mid-November 2022 , with deliveries expected to occur by the end of 2022 or early 2023.

During the first nine months of 2022, the Company produced approximately 205 tonnes of mixed partially separated carbonate (" RE Carbonate "), containing approximately 95 tonnes of total rare earth oxides (" TREO "). Energy Fuels' partially separated RE Carbonate contains a higher concentration of valuable NdPr, roughly 32% - 34% NdPr, compared to our previously produced non-separated RE Concentrate which contained approximately 22% NdPr, and is the most advanced REE material being produced in the U.S. today. During Q4-2022, the Company expects to receive approximately 640 tonnes of monazite, which will be processed into partially separated RE Carbonate during Q4-2022 and Q1-2023.

In May 2022 , the Company announced it had entered into agreements to acquire a 58 square mile rare earth land position in Brazil (the " Bahia Project "). The Bahia Project is a well-known heavy mineral sand (" HMS ") deposit that has the potential to feed the Company's White Mesa Mill with REE and uranium-bearing monazite sand for decades. Due diligence on the Bahia Project was completed at the end of August, at which time the Company advised the sellers that it intended to proceed with the purchases and was ready to commence closing procedures. After completion of a number of administrative logistics required in both the U.S. and Brazil , the mineral transfers were initiated in mid-November, and closing is currently expected to occur in late 2022 or early 2023 upon approval of the Brazilian governmental authorities reviewing the pending transfers. Upon acquisition, the Company plans to conduct an extensive exploration program to better define the HMS and monazite resource, including comprehensive sonic drilling (for a total phase 1 program of 2,250 meters) and geophysical mapping, with the intent to undertake an Initial Assessment under SK-1300 (U.S.) and a Technical Report under NI 43-101 ( Canada ) during Q4-2023, to be completed in early Q1-2024.

The Company is currently in active discussions with several additional sources of natural monazite sands around the world to significantly increase the supply of feed for our growing REE initiative.

The Company continues to make excellent progress toward installing full REE separation capabilities at the Mill to produce both "light" and "heavy" separated REE oxides in the coming years. The Company plans to initially install a "light" REE separation circuit within the existing Mill facilities in the next 12-18 months with the expected ability to produce between 2,500 – 5,000 tonnes TREO (500 – 1,000 tonnes NdPr oxide or oxalates) per year. As this circuit would be constructed within existing Mill facilities, capital expenditures are expected to be low. The Company is also proceeding with the design, engineering and permitting of a separate crack and leach circuit and a second larger "light" and "heavy" separations circuit with capacity in the order of 10,000 – 15,000 tonnes TREO per year to provide additional REE processing capacity at the Mill in the coming years.

During the first nine months of 2022, the Company soldapproximately 642,000 pounds of existing inventory of vanadium (" V 2 O 5 ") (as ferrovanadium, " FeV "), for anaverage weighted net price of $13.69 per pound of V 2 O 5 . Vanadium markets have dropped in recent months. Therefore, the Company has halted sales of its inventory which currently stands at approximately 987,000 pounds of V 2 O 5 . However, the Company expects to resume sales as markets may improve in the future. The Company is evaluating the potential to resume vanadium recovery at the Mill in the future as market conditions may warrant for future sale and to replace sold inventory, where its tailings pond solutions contain an estimated additional 1.0 to 3.0 million recoverable pounds of V 2 O 5 .

Energy Fuels Inc. (UUUU), closed Friday's trading session at $6.91, up 3.1343%, on 1,730,225 volume. The average volume for the last 3 months is 32,194 and the stock's 52-week low/high is $4.69/$11.39.

Recent News

Golden Matrix Group Inc. (NASDAQ: GMGI)

The QualityStocks Daily Newsletter would like to spotlight Golden Matrix Group Inc. (NASDAQ: GMGI).

Golden Matrix Group (NASDAQ: GMGI) , a developer and licensor of gaming platforms, systems and gaming content, has acquired the remaining 20% interest in RKings Competitions; the company now owns a total of 165,444 restricted shares of GMGI’s common stock payable to the two former owners of RKings. Company officials announced the transaction, which makes RKings a wholly owned entity of Golden Matrix, one which the company anticipates will grow quickly in several regulated jurisdictions, including Great Britain and Mexico. The company plans to expand the tournament platform into other Latin American markets in the next few years. In addition, Golden Matrix recently launched GMGI Assets, a complementary business designed to enhance the revenue stream and profit being generated by the RKings division. “As an example, and in some instances, the tournament winner of an expensive automobile may choose to take a predetermined cash option in lieu of the car,” said Golden Matrix Group CEO Brian Goodman in the press release. “When this occurs, GMGI Assets will take possession of the car and resell it. Each transaction has a built-in positive margin, and we expect this business to make significant contributions to GMGI’s overall financial results as the number of auto tournament offerings continues to grow in Great Britain, as well as additional jurisdictions in the future.” To view the full press release, visit

Golden Matrix Group Inc. (NASDAQ: GMGI), based in Las Vegas, Nevada, is an established gaming technology company that develops and owns online gaming IP and builds turnkey online casino solutions for gaming operators as well as configurable and scalable white-label gaming platforms for international customers, located primarily in the Asia-Pacific region. GMGI’s gaming IP includes tools for marketing, acquisition, retention and monetization of users. The company’s platform can be accessed through both desktop and mobile applications.

GMGI’s sophisticated software automatically declines any gaming or redemption requests from within the United States, in strict compliance with U.S. law.

Golden Matrix, through a subsidiary, also runs a pay-to-enter prize competition in the United Kingdom and Ireland.

The company’s shares began trading on the Nasdaq under the symbol ‘GMGI’ on March 17, 2022. Golden Matrix shares were previously traded on the OTCQX Best Market.

For the quarter ended January 31, 2022, the company reported revenue of $8.88 million, an increase of 355% over the same quarter one year earlier. Net income for the three-month period was $349,379, up from $52,158 a year earlier. It was the company’s 14th consecutive profitable quarter.

In December 2021, Golden Matrix announced it had entered into a purchase agreement to acquire a controlling ownership interest in UK-based RKingsCompetitions Ltd., one of Ireland’s and the United Kingdom’s leading independent online competition companies. RKings presents customers with paid and free entry routes to competitions that offer a range of prizes, including residential properties, luxury and exotic motor vehicles, holiday packages, technology packages and cash. The competitions are currently open only to residents of Ireland and the United Kingdom. Golden Matrix acquired an 80% ownership interest in RKings for cash and stock. The company also secured an option to purchase the remaining 20 percent interest of RKings, subject to certain requirements.

In March 2022, Golden Matrix announced it had applied for a Mexican gaming permit and, once approved, expects to offer online gaming in Mexico as well as roll out the RKings tournament business globally.


Golden Matrix Group develops fully operational online casino turnkey solutions as well as highly modular, configurable and scalable gaming platforms for its international customers in an effort to promote user acquisition, engagement, retention and monetization. The provided white label gaming platform is unparalleled in both mobile and desktop website deployment, proving compatible throughout all major operating systems and web browsers. In addition, the platform enhances the client’s ability to cater to various gaming scenarios including but not limited to transaction management and a range of loyalty and reward programs. Moreover, user engagement is optimized through the ability to accommodate both free and paid games.

The company’s GM-X System (and recently its next generation GM-Ag System) is considered the industry standard, granting access to over 10,000 games from more than 25 game providers. Through the GM-X System, Golden Matrix offers the industry’s most extensive game portfolio. The company’s gaming partners dominate the global online gaming market to deliver innovative games and premium brand titles. The GM-X System offers payment gateways that integrate with third party platforms or digital wallets. It supports all major currencies and offers multiple language options. The system’s data analytics provide the operator with a 360-degree view of the gaming platform’s performance.

GMGI currently supports over 500 unique casino brands and over 6 million players.

Market Outlook

Online gaming and sports betting sites and apps are increasingly taking market share from traditional location-based casinos. Widespread internet service availability and increasing use of mobile phones for playing online games from homes and public places is driving the market, according to a report from Grand View Research. In addition, factors such as easy access to online gambling, legalization and cultural approval, corporate sponsorships, and celebrity endorsements are also contributing to market growth. The growing availability of cost-effective mobile applications across the globe is further expected to fuel market growth.

This trend is only expected to accelerate as millennials reach their peak earning years and Gen Z youth begin to complete their education and move into careers. These generations are completely comfortable with online recreation, and with using technology like digital wallets and digital gameplay that underpins online gaming.

The global online gambling market was valued at $53.7 billion in 2019 and is expected to grow at a CAGR of 11.5% from 2020 to 2027 to reach a value of $127.3 billion, according to Grand View Research, with much of the growth expected from the U.S. and Asia. Even Europe, the most mature gaming market, is expected to grow at a rate of 20-25% year-over-year.

Management Team

Brian Goodman is CEO of Golden Matrix Group. He has more than 20 years of diverse senior management experience and business development roles within the technology and internet gaming industries. He has a tertiary science qualification as well as a marketing and sales background. His previous roles have been entrepreneurial and include CEO and senior management positions in smaller organizations, which he founded or in which he held equity, as well as multinational organizations.

Cathy Feng is COO at Golden Matrix. She is a co-founder of GMGI and holds a Master of Commerce degree. She has 10 years of experience as a financial officer in the technology and internet gaming industries. In past management positions, she interpreted, analyzed and presented financial and operation information to facilitate business decisions, grow companies and resolve complex problems. In addition, she has skills in marketing, business development, leadership and strategic planning.

Omar Jimenez is CFO and Chief Compliance Officer at GMGI. Prior to joining the company, he was CFO and COO of Alfadan Inc., a supplier of marine outboard engines. He has held senior financial management and operational positions at public and private companies including NextPlay Technologies, American Leisure Holdings, US Installation Group and Onyx Group. He holds various accounting professional certifications, including CPA and CPCU, and degrees in finance, accounting and business.

Henry Zhang is Chief Technology Officer at Golden Matrix. He oversees all aspects of development, integration and deployment of GMGI’s technology systems. He plays a key role in evolving GMGI’s technology business to lead and shape the industry. He is responsible for developing and scaling new businesses, including online gaming, eSport and P2P Systems. He was instrumental in launching the GM-X system and has been with the company for more than six years.

Golden Matrix Group Inc. (NASDAQ: GMGI), closed Friday's trading session at $2.95, up 3.8732%, on 32,194 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $11.39/$.

Recent News

FuelPositive Corp. (TSX.V: NHHH) (OTC: NHHHF)

The QualityStocks Daily Newsletter would like to spotlight FuelPositive Corp. (NHHHF).

FuelPositive (TSX.V: NHHH) (OTCQB: NHHHF) , a growth-stage enterprise focused on opportunities relating to energy-efficient technology and sustainability, is pushing for the production of green ammonia that consumers can afford while, at the same time, addressing issues that are currently being felt on a global scale. “According to FuelPositive, a sure way to help guarantee food security and reduce the over-reliance on global supply chains is to empower farmers. This, it argues, starts with disrupting the fertilizer sector, specifically the traditional ammonia sector. Its onsite, containerized green ammonia production system allows farmers to produce their own nitrogen fertilizer on their farms, without relying on traditional ammonia producers or supply chains,” reads a recent article. “FuelPositive is offering stability in supplying the necessary fertilizer for crop production and its cost. Ultimately, the company is bringing the overall cost of farming significantly lower, making food even more affordable for a growing population… The company is optimistic that its efforts will benefit farmers in particular by allowing them to produce what they need, when and where they need it, at a stable cost.” To view the full article, visit

FuelPositive Corp. (TSX.V: NHHH) (OTC: NHHHF) is a growth stage company focused on licensing, partnership and acquisition opportunities building upon various technological achievements. The company is committed to providing commercially viable and sustainable clean energy solutions, including carbon-free ammonia (NH3), for use across a broad spectrum of industries and applications.

FuelPositive is headquartered in Toronto, Canada.

Hydrogen Economy Problems and FuelPositive’s Carbon-Free Technology

The hydrogen economy is currently facing many challenges. Traditional NH3 manufacturing exists on a massive scale, but centralized facilities result in some of the world’s most concentrated CO2 emissions. In total, an estimated 200 million metric tonnes of NH3 are consumed each year, with greater than 80% utilized by the agricultural sector. NH3 is also being positioned as a viable alternative to fossil fuels.

FuelPositive’s flagship carbon-free ammonia technology provides an innovative solution to these environmental concerns. Developed by Dr. Ibrahim Dincer and his team, the company’s platform allows for the in-situ production of NH3 in an entirely sustainable manner, using only water, air and sustainable electricity.

The production of hydrogen is energy intensive, but it is just one variable hindering the growth of the hydrogen economy. Other hurdles include:

  • Storage – The storage of hydrogen by compression or liquification are both cost prohibitive and unsustainable.
  • Distribution – The distribution network for effective hydrogen deployment has yet to be developed, as the extreme high-pressure distribution requirements to transport hydrogen would result in enormous infrastructure costs.
  • End Use – R&D on the transportation-related end use applications for hydrogen is in its infancy, but almost any vehicle on the road today can be easily converted to run on NH3 at a considerably lower cost per mile traveled when compared to traditional fossil fuels.

A key benefit of FuelPositive’s patent-pending, first-of-its-kind carbon-free NH3 technology is its flexibility. The process allows for small, medium or large-scale production of NH3 on location, minimizing or even eliminating the challenges and volatility associated with storage and transportation to end use. As such, with an appropriately sized FuelPositive system and access to renewable energy, the end use applications for the company’s platform are nearly infinite.

Manufacturing Partnership

On May 19, 2021, FuelPositive announced its selection of National Compressed Air Canada Ltd. (“NCA”) to undertake manufacturing of the company’s Phase 2 hydrogen-ammonia synthesizer commercial prototype systems for carbon-free ammonia production.

In a news release detailing the partnership, FuelPositive CEO Ian Clifford noted, “This critical milestone for FuelPositive will confirm the broad application potential for our technology and is the backbone of our Carbon-Free Hydrogen-NH3 offering. Partnering with the knowledgeable and experienced team at NCA on this commercialization project will bring our development-stage program to life.”

Global Ammonia Market Outlook

The global ammonia market was valued at $52.71 billion in 2017 and is forecast to reach $81.42 billion by 2025, growing at a CAGR of 5.59%, according to data from Fior Markets (

The agricultural industry consumes more than 80% of global NH3. Smaller percentages can be attributed to the waste, water treatment, refrigerants, antiseptic, textile, mining and pharmaceutical industries.

One of the most polluting industries on the planet consists of conventional agribusinesses. These polluters are responsible for more greenhouse emissions per year than transportation. This is where FuelPositive’s technology is expected to be extremely beneficial.

Management Team

Ian Clifford is Director, CEO and Founder of FuelPositive Corp. He has over 25 years of experience in the fields of technology and marketing and has successfully led the company to global brand recognition through its unique energy solutions. Since 2006, Mr. Clifford has raised over $50 million in equity financing for FuelPositive. He also co-founded digIT Interactive, a full-service internet marketing company serving Fortune 500 clients, which he sold at the peak of the market in 2000.

Greg Gooch serves as a Director and President of FuelPositive. His multifaceted career in the electronics and finance industries has positioned him as a key advisor and funding partner to start-ups and new technology companies for over 40 years. Mr. Gooch has been involved with FuelPositive since its early days and has remained a significant supporter and consultant to the company over the years. He has a bachelor’s from McGill University and an MBA from the University of Western Ontario.

Dr. Ibrahim Dincer is a scientific advisor to FuelPositive and is recognized as a pioneer and international leader in the area of sustainable energy technologies. Along with his team, Dr. Dincer invented the modular carbon-free ammonia (NH3) production technology that FuelPositive is commercializing. His area of specialty covers various topics including ammonia, hydrogen energy and fuel cells; renewable energy systems; energy storage systems and applications; carbon capturing technologies, and integrated and hybrid energy systems He is currently managing an exemplary team of researchers in this commercialization project.

Marek Warunkiewicz is the company’s Communications & Branding Specialist. He brings more than 40 years of entrepreneurial expertise to the FuelPositive team, having held marketing, branding, advertising, project management and graphic design positions with various companies. Mr. Warunkiewicz has successfully created business-to-business marketing and advertising campaigns for a diverse group of clients ranging from high-tech to agriculture. He co-founded digIT Interactive and ZENN Motor Company alongside Ian Clifford.

Luna Clifford is the Director of Communications for FuelPositive. She has over 10 years of experience as a business owner and advisor, helping build and operate several successful start-up enterprises while managing complex stakeholder relationships. Ms. Clifford excels in strategic planning and team building, and she has completed extensive studies in the fields of communications and health care.

FuelPositive Corp. (NHHHF), closed Friday's trading session at $0.1025, up 2.5%, on 104,015 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.0789/$0.201.

Recent News

India Globalization Capital Inc. (NYSE American: IGC)

The QualityStocks Daily Newsletter would like to spotlight India Globalization Capital Inc. (NYSE American: IGC).

India Globalization Capital Inc. (NYSE American: IGC), through subsidiary IGC Pharma, develops, patents, and markets advanced THC-based drug formulations for the treatment of symptoms related to various diseases including but not limited to Alzheimer’s disease, Tourette syndrome, chronic pain, and pet seizures.

IGC’s leading drug candidate, IGC-AD1, has completed Phase 1 of a safety and tolerability trial and entered Phase 2 trials for treating agitation in patients with Alzheimer’s dementia, the first study in humans of a natural tetrahydrocannabinol (THC) compound plus another molecule ( As of September 2022, the IGC trial is the only ongoing Phase 2 trial of a natural THC-based formulation on Alzheimer’s patients.

The company’s other drug candidate, TGR-63, is an enzyme inhibitor that has shown in preclinical trials the potential to reduce neurotoxicity in Alzheimer’s cell lines. Both drug candidates have shown their ability to ameliorate beta amyloid plaques in Alzheimer’s cell lines and improve memory in Alzheimer’s mouse models. Beta amyloid plaques are a key hallmark of Alzheimer’s and an important target of Alzheimer’s pharmaceutical drug development.

Neuro Psychiatric Symptoms (NPS) are not only debilitating for Alzheimer’s patients; they also place an immense emotional burden on their caregivers. Beyond reducing symptoms, IGC-AD1’s active molecules and TGR-63 have also shown promise in preclinical trials to reduce important hallmarks of Alzheimer’s including plaques and tangles, as well as improving the treatment of memory loss.

Over the past eight years, the IGC team has amassed a deep knowledge of cannabinoid science, including extraction, isolation, purification, and development. The company’s strategy is to leverage its unique end-to-end capabilities, platform, and expertise to develop a class-leading program and bring it to market quickly and cost efficiently to treat neurodegenerative diseases such as Alzheimer’s.

The company also has a family of cannabidiol (CBD)-based consumer products ( such as pain relief creams, pain relief gels, purpose gummies, tinctures, and capsules targeting women’s wellness, with a particular focus on premenstrual syndrome (PMS) and dysmenorrhea (period cramps). In addition, the company targets individuals that need sleep-aids with its specially formulated low melatonin cannabinoid gummies.

IGC has also introduced a low-calorie CBD- and caffeine-infused energy beverage brand ( that is currently available for purchase. The company’s brands are founded on the belief that effective natural solutions should be affordable and accessible to everyone. As the demand for natural products targeting women’s wellness and energy drinks continue to grow, these products are seeing strong traction in the market.

The company operates three facilities – a large GMP (Good Manufacturing Production Standards) certified facility that includes extraction, distillation, and manufacturing, in Washington State; a GMP-211 (pharmaceutical) grade facility in Maryland; and a facility licensed for controlled substances including cannabis in Bogota, Colombia, with complete access to legal licensed cannabis where the company conducts its testing.

In addition, the company’s development under Magistral Formulations is approved by INVIMA (Colombia National Food and Drug Surveillance Institute) to treat neurological disorders, non-oncological chronic pain, and mental disorders.

IGC’s intellectual property (IP) portfolio comprises of eight patents that it controls and seven patent applications. The portfolio includes #11,446,276, a patent for extreme low dose THC treatment of Alzheimer’s that was granted in September 2022.

The company is headquartered in Potomac, Maryland.


IGC-AD1 is the company’s leading drug candidate for the treatment and relief of Alzheimer’s symptoms. A significant amount of research on Alzheimer’s cell lines has shown that the active agents in IGC-AD1 reduce plaques and neurofibrillary tangles that are the hallmarks of Alzheimer’s. Further, micro-dosing of THC, as shown in cell lines, could increase the functioning of mitochondria and potentially promote the growth of new neural pathways (neurogenesis). The research shows that micro-dosing of THC affects the brain radically differently from the normal higher dosing of THC.

While there is a significant body of research showing that THC is neuro-toxic at normal levels of dosing, micro-dosing of THC has been shown to be non-toxic to neurons. With the results of these preclinical studies, the company developed an oral formulation, IGC-AD1. The company recently completed a safety and tolerability Phase 1 trial on Alzheimer’s patients and has initiated a Phase 2, multi-site, double-blind, randomized, placebo-controlled trial of the safety and efficacy of IGC-AD1 on agitation in participants with dementia due to Alzheimer’s disease at sites in the U.S. and Canada. IGC expects the Phase 2 trial to take between 9 and 12 months to complete, barring unknown factors such as, for example, a resurgence of COVID and the enforcement of lockdowns and travel restrictions.

With further successful trials and FDA approvals, IGC hopes to bring a drug based on natural THC as an effective treatment for agitation in Alzheimer’s to market.


The company’s other molecule, TGR-63, has been shown to reduce the neurotoxicity that impacts memory loss in preclinical trials with mice. On a dose dependent manner, transgenic Alzheimer’s mice treated with TGR-63 showed improvement in memory relative to control.

Both drug candidates, IGC-AD1 and TGR-63, have shown their ability to reduce the brain plaques associated with memory loss in Alzheimer’s in mice.

With further successful trials and FDA approvals, IGC hopes to bring TGR-63 as a treatment for Alzheimer’s disease to market.

Market Opportunity

Alzheimer’s disease impacts over 55 million people worldwide and about 5.5 million individuals in the U.S. Over 70% of these patients face debilitating symptoms, including anxiety, depression, and agitation (Mendez, 2021). Agitation in dementia patients can include excessive physical movement and verbal activity, restlessness, pacing, belligerence, aggression, screaming, crying, and wandering.

In 2020, the estimated healthcare costs for Alzheimer’s disease in the U.S. were $305 billion. Medicare and Medicaid covered about 70% of those costs, leaving considerable burden on patients and families. At the current rate of growth of Alzheimer’s and other dementia diagnoses, those costs are estimated to reach over $1 trillion by 2050.

Currently, there are no FDA-approved medications to alleviate the symptoms of dementia due to Alzheimer’s disease, providing a tremendous opportunity for formulations that can have an impact on quality of life and disease progression.

Management Team

Richard Prins has been chairman at IGC since 2012 and served as an independent director since 2007. From March 1996 to 2008, he was the Director of Investment Banking at Ferris, Baker Watts, Incorporated. Prins served in a consulting role to RBC until January 2009. He currently volunteers full time with a non-profit organization, Advancing Native Missions, and is a private investor. Since February 2003, he has been on the board of Amphastar Pharmaceuticals Inc. He holds a bachelor’s degree from Colgate University and an MBA from Oral Roberts University.

Ram Mukunda is CEO and President of IGC. He has been the chief inventor and architect of most of the company’s patent filings and is responsible for the company’s strategic positioning. Prior to IGC, he was founder and CEO of Startec Global Communications, which he took public in 1997. He served as Strategic Planning Advisor at Intelsat, a communications satellite services provider. From 2001 to 2003, he was a Council Member at Harvard’s Kennedy School of Government, Belfer Center of Science and International Affairs. He was named the 1998 Ernst & Young Entrepreneur of the Year. He holds bachelor’s degrees in electrical engineering and mathematics, and a master’s degree in engineering from the University of Maryland.

Dr. Jagadeesh Rao is the company’s Principal Scientist. His career spans two decades in the public sector and product R&D for Johnson & Johnson. He leads IGC’s scientists in the development of pharmaceutical and OTC products. He worked for the federal National Institutes of Health, and for the National Institute on Drug Abuse. His Ph.D. in Neurochemistry is from the National Institute of Mental Health & Neurosciences in India. He did postdoctoral training at the University of Illinois-Chicago.

Claudia Grimaldi is a Director, Vice President, Principal Financial Officer, and Chief Compliance Officer for IGC. She also serves as a Director/Manager Director for some of the company’s subsidiaries. She graduated with highest honors from Javeriana University in Colombia with a bachelor’s degree in psychology. She holds an MBA, graduating with highest honors, from Meredith College in North Carolina. In addition, she has attended the Darden School of Business Financial Management Executives program and the Corporate Governance Program at Columbia Business School. She is currently pursuing her Directorship Certification with the National Association of Corporate Directors. She is fluent in both English and Spanish.

India Globalization Capital Inc. (NYSE American: IGC), closed Friday's trading session at $0.425899, up 1.4045%, on 63,779 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.40/$1.61.

Recent News

REZYFi, Inc.

The QualityStocks Daily Newsletter would like to spotlight REZYFi, Inc.

According to the latest statistics from Viridian Capital Advisors, more and more marijuana companies are opting for debt financing as opposed to equity financing in the United States. Viridian Capital Advisors is a company that advises marijuana entities on strategy and M&A as well as on how to access or raise capital. According to Viridian Capital, debt financing now commands 93% of all financing secured by marijuana companies that focus on retail or cultivation, while the industry average for debt financing stands at 55.7%. It should be noted that year-to-date figures show a decline in both equity financing as well as debt financing, but the current figures show an uptick in debt financing. One reason for this trend is that many marijuana firms are maturing and they have their act in order, which means that financiers can look at their balance sheets and lend them money based on their cash flows. Given that many firms are actually earning revenues, it is easier for them to repay loans, and that makes debt financing a better option to equity financing. Such possibilities several months or years down the road could impact the benefit derived from debt financing, and Viridian Capital cautions that care has to be taken because lenders will do what is within their rights to protect their investments and earn a profit. Since each company is different, companies such as REZYFi Inc. will probably table their own unique positions if and when they need to raise more money to capitalize on an opportunity or get breathing space if they ever face liquidity issues.

REZYFi, Inc. is a cannabis mortgage bank servicing the needs of both traditional and non-traditional consumers and businesses. Its target markets include licensed and permitted cannabis companies, owners of real estate who lease to cannabis companies, and companies and individual homeowners seeking a variety of real estate-related first and additional mortgage-based financing and project-specific financings, such as solar installations and real estate development projects.

Headquartered in Miami, Florida, REZYFi operates through two wholly owned subsidiaries – REZYFi Lending, which primarily addresses emerging real estate-related financing opportunities, and ResMac Inc., the company’s traditional mortgage origination, correspondent and servicing operation. REZYFi is currently licensed in 34 U.S. states, with plans to expand to all remaining states later this year.

REZYFi is positioned as one of first cannabis mortgage bankers in the U.S., while most traditional lenders are still reticent to serve the state-licensed cannabis industry.


REZYFi Lending

REZYFi Lending leverages a wide network to offer options such as 15- and 30-year fixed-rate loans, FHA loans, VA loans, reverse mortgages, jumbo loans and adjustable-rate mortgages.

Looking ahead, the company expects increased funding in marketing and loan agents to drive significant origination growth over the next two years, further supported by the planned launch of a high-margin cannabis division later this year.

ResMac Inc.

ResMac has been in operation for 13 years, having closed more than 20,000 loans for more than 15,000 clients. The company expects to accumulate $285 million in retail origination in 2023, alongside $250 million in wholesale origination for the same period. ResMac is further targeting $600 million in origination through its mortgage correspondent operations for 2023.

Through its ResMac subsidiary, REZYFi operates as a direct lender and originator of residential mortgages, with active mortgage correspondent and mortgage servicing operations. Through its correspondent segment, ResMac primarily purchases and aggregates residential mortgages from trusted third-party originators.

The company intends to harvest the database of customers within its mortgage servicing operations as an essential source of additional growth, especially relative to the new alternative residential loan programs being offered.

Corporate Strengths

  • Experience – REZYFi is led by a seasoned management team with significant expertise spanning a wide range of real estate and financing subsectors. The team also has extensive experience in the cannabis and hemp marketplace, which the company intends to leverage as it navigates the changing landscape of the cannabis industry while sourcing the best opportunities in the sector.
  • Network of Independent Brokers – Over the past five years, REZYFi has developed an extensive network of independent mortgage-related brokers and licensed loan officers. The company is currently training the network members on its new service offerings, with many already launching sales efforts. REZYFi believes this network will be a vital asset moving forward as other firms in the sector terminate relationships in the face of slowing mortgage business in a rising interest rate environment.
  • Proprietary Technology – REZYFi has invested heavily in designing, building and implementing proprietary automated/machine learning technology to shorten loan processing timeframes and increase efficiencies, allowing it to operate its legacy business at staffing levels meaningfully below those of its competitors.

Market Overview

REZYFi’s diversified approach to the real estate lending sector positions it to capitalize on growth in multiple verticals in the years to come.

In the first quarter of 2022, lenders issued 2.71 million residential loans, with the average balance for a first mortgage climbing to a record high of $298,324 in 2021, according to the Mortgage Bankers Association. This trend is expected to continue, with Freddie Mac forecasting a 10.4 percent increase in home prices in 2022 and a 5.0 percent bump in 2023. Growth prospects in the cannabis industry paint a similar picture.

The National Association of Realtors® issued a report in April 2021 examining the correlation between cannabis legalization and real estate demand. In states where prescription and recreational cannabis use is legal, more than a third of surveyed agents reported an increase in demand for warehouses. Likewise, 23 percent of those surveyed reported an increase in demand for storefronts, and 28 percent observed increased demand for land. As other states look to join the 19 that have embraced full cannabis legalization, this rising demand could create an opportunity for REZYFi’s cannabis-focused initiatives.

In total, an analysis by market research firm Business Research Insights projects the global loan servicing market to reach a value of nearly $1.5 billion by 2028, up from $680.8 million in 2021. Those figures represent a CAGR of 11.0 percent during the forecast period of 2022-2028.

Management Team

John Vu, Esq., is CEO of REZYFi, Inc. He has more than two decades of experience in the mortgage and commercial banking industry. He has filled many senior and executive management positions in high-producing mortgage banks, including C-level assignments. He has also served as general counsel for a nationally associated commercial bank. Mr. Vu brings considerable cannabis industry expertise to REZYFi. He has served as a corporate attorney to multiple cannabis cultivators, manufacturers and retailers.

Ji Ji Zhang, Esq., is CFO of REZYFi, Inc. He is a multifaceted entrepreneur who owns a law firm, a portfolio of hotels and a high-producing mortgage bank. Mr. Zhang is also an investor in the development of a cannabis business park. He brings more than five years of experience in mortgage banking to REZYFi, having developed Freddie Mac and HUD licenses and amassed a managed portfolio valued at over $300 million.

Kevin Heckemeyer is President of REZYFi, Inc. He has more than 25 years of experience in mortgage banking. He has built and sold several high producing mortgage businesses. In his current roles with ResMac, he is responsible for production and operations.

Spencer Dang is Chief Credit Officer of REZYFi, Inc. He has more than a decade of experience in mortgage operations. He is a direct endorsement underwriter for HUD and has specialized in non-QM underwriting. Under his watch as an underwriter, he has never had a single repurchase.

Recent News


Correlate Infrastructure Partners Inc. (OTCQB: CIPI)

The QualityStocks Daily Newsletter would like to spotlight Correlate Infrastructure Partners Inc. (OTCQB: CIPI).

Commercial buildings in the United States consume 35% of all electricity in the country while accounting for 16% of emissions in the country. Buildings, in general, account for over 60% of emissions, with large business centers responsible for as much as 70%

With 80% of building stock that will be standing in 2050 already built, the only remaining solution is to retrofit these buildings with renewable energy sources to meet the 2050 net zero targets

Correlate is looking to meet this demand and solve the challenges associated with it by offering a more cost-effective approach with its finance program

It prides itself on its transparency and fair pricing, which, its management argues, are enablers of green energy adoption within different sectors, including the real estate industry

By laying down, the groundwork for the energy transition, Correlate is carving out a decent market share in the North American market and is growing its customer numbers, as evidenced by its $100 million opportunity pipeline in commercial projects and $20 million in awarded backlog

It is estimated that over 60% of carbon emissions within cities in the United States come from buildings, and some of the large business centers account for as much as 70%. With 80% of building stock that will be standing in 2050 already built, the only remaining solution to this growing issue is retrofitting these buildings with renewable energy sources, mainly since new buildings and construction alone will not get society to the 2050 net zero targets ( ). Correlate Infrastructure Partners (OTCQB: CIPI) , a portfolio-scale real estate platform, recognizes the problem at hand and the challenges associated with making existing buildings achieve their net-zero targets. With its focus on renewable energy, specifically solar, the company is offering a more cost-effective approach towards reducing buildings’ and companies’ carbon footprint while also allowing them to be self-sustaining from an energy standpoint.

Correlate Infrastructure Partners Inc. (OTCQB: CIPI), formerly Triccar Inc., through its two subsidiaries, Correlate and Solar Site Design, offers a complete suite of proprietary clean energy assessment and fulfilment solutions for the commercial real estate industry. The company believes scaling distributed clean energy solutions is critical in mitigating the effects of climate change. CIPI is at the forefront in creating an industry-leading energy solution and financing platform for the commercial and industrial sector. The company sees tremendous market opportunity in reducing site-specific energy consumption and deploying clean energy generation and energy efficiency solutions at scale.

The opportunity exists to remove friction between today’s legacy finance process and the needed clean-energy upgrades developed within the company’s program technologies. For the U.S. to reach its 2050 carbon goals, 200,000 commercial buildings must be retrofitted every year until that date. That represents approximately a 5-10x increase over the 2022 industry process run rate.

CIPI announced completion of its acquisition of 100% of the equity of Correlate Inc. and Loyal Enterprises LLC dba Solar Site Design on December 28, 2021. The company notes these acquisitions occurred at a key inflection point of its growth. CIPI currently enjoys channel and sales partnerships with Fortune 250 companies and a strong, proven industry network.

The company’s transparent, leading-edge model changes value delivery for both facility owners and proven solution providers seeking scale. CIPI believes its rapid growth is due to industry demand for actionable, cashflow positive energy programs and the underlying carbon reduction mandates taking effect globally.

CIPI has filed with the SEC for a name change to Correlate Infrastructure Partners Inc., which will more closely reflect its new platform and growth focus. The company has been aggressively moving to rebrand, with efforts including a revised website, investor presentation materials and an investor relations awareness campaign. The company’s shares will continue to trade on the OTCQB Venture Market under the current ‘CIPI’ ticker symbol until changes are approved.


Correlate, founded in 2015, is a portfolio-scale development and finance platform offering commercial and industrial facilities access to clean electrification solutions focused on locally-sited solar, energy storage, EV infrastructure, and intelligent efficiency measures. Its unique data-driven approach is powered by proprietary analytics, concierge subscription services, and a highly scalable national fulfillment network to help building owners profit from fully funded, turnkey decarbonization and facility health programs. The platform is designed for commercial and industrial real estate owners seeking to significantly improve net operating income while meeting carbon reduction goals. The platform provides energy programs for commercial property portfolios and requires no upfront capital. Client organizations reduce their risk and generate more profits by leveraging Correlate’s unique payment programs to put more cash in the bank. Deploying Correlate’s strategic energy programs and energy management systems allows property-owning organizations to complete big energy changes across their portfolios.

Solar Site Design, founded in 2013, is a U.S. Department of Energy Sunshot Catalyst winner that provides customer acquisition and project development tools for the commercial solar industry. Its commercial marketplace platform connects highly qualified project opportunities to leading solar construction companies nationwide. The Solar Site Design platform gives commercial and industrial property owners access to the best price for a commercial solar system. Commercial solar analysts provide property owners a site assessment and working project proposal. Solar Site Design’s team of solar engineers finalize the design while approved financing providers help clients explore financing options for their projects. Then, approved contractors in Solar Site Design’s Marketplace bid on the projects, ensuring commercial and industrial property owners get the best estimates for their projects. Solar Site Design’s marketplace process promotes transparency and fair pricing. Its team of experts has nearly 20 years of experience in the solar industry. Only reputable, experienced, certified (NABCEP), licensed, bonded and insured contractors are accepted into the Solar Site Design Marketplace.

Market Outlook

CIPI is in a rapidly growing market with a unique offering to address a total market of more than 5.9 million commercial buildings in the United States, according to the U.S. Energy Information Administration. Currently, the company’s wholly owned subsidiaries, Correlate and the Solar Site Design, have an opportunity pipeline of over $100 million in commercial projects with more than $20 million in awarded backlog. According to the Rocky Mountain Institute, portfolio energy optimization is a $290 billion market in the United States driving deep financial savings and energy efficiency across the commercial sector.

Commercial buildings consume more than 35% of the generated electricity in the U.S. and are underperforming in energy efficiency at every level. These buildings waste energy, emit too much carbon, and are too costly for owners and occupants, but retrofits are not happening at the rate or scale needed.

In today’s real estate market, portfolio property owners own most commercial buildings. Yet most building efficiency work is focused on single buildings, thereby missing the distinct needs of this owner class which has very different needs than traditional owner-occupiers. The diverse nature of commercial buildings, combined with technology and performance uncertainty, make simple energy optimization initiatives – which could greatly reduce energy use and improve building value – financially unattractive, resulting in slow adoption rates. CIPI’s financial instruments and software breakdown this issue known as the “split incentive”, unlocking the majority of the addressable market.

Management Team

CIPI has in place a nationally recognized management team that has been active in the energy market since 2005.

Todd Michaels is President and CEO of CIPI and founder of Correlate. He formerly served as Vice President for Innovation at SunEdison and Senior Director Distributed Solar at NRG Energy. He founded Correlate in 2015 and has 16 years of experience in the energy industry. He graduated from Indiana University with a B.S. in Computer Information Systems.

Channing Chen is CFO at CIPI and Correlate Inc. and brings over 16 years of experience in the solar industry as a developer, financier, and business unit leader. He has held executive management roles at Solar Power Partners (acquired by NRG Energy), where he was a founding employee, SunEdison, and NRG Energy (NYSE: NRG). Most recently, Mr. Chen was founder and Managing Partner at Breakaway Energy Partners LLC – a distributed energy financing and market-making platform. To date, Mr. Chen and his teams have raised over $1.5 billion in financing across residential, commercial, and utility scale solar and energy storage projects representing over 400 MWs. He holds a B.A. in Environmental Chemistry from the University of California at San Diego and an MBA from the University of Southern California. He is also an advisor and early-stage investor to several startup companies in the renewable energy space.

David Bailey is Chief Revenue Officer of Correlate Inc. With over 15 years of executive sales, supply chain management, and energy efficiency experience, he is responsible for ensuring the success of the National Commercial Sales Unit across multiple regional project teams. Mr. Bailey created and launched the Transformation Services team while at Wesco for its multibillion-dollar Distributed Energy Resource division, formerly Westinghouse. His focus was on IoT-enabled efficiency and plant floor automation-based services. Before that, he spent several years in Global Account Sales Management, with GE Supply as a Program Manager, and is a Commercial Leadership Program graduate. Mr. Bailey received his B.S. in Mechanical Engineering from the University of Kentucky.

Jason Loyet is VP of Commercial Sales of Correlate Inc. He is a cleantech executive with over 20 years of experience leading high growth solar energy and software start-ups. Mr. Loyet is a U.S. Department of Energy SunShot Catalyst award winner for his work building the Solar Site Design technology platform. Before joining the solar energy industry in 2005, he founded and sold two software companies in the streaming media (GlobalStreams) and newspaper publishing (MyCapture) industries. Mr. Loyet currently serves as a Member of the Board of Directors for the Tennessee Solar Energy Industry Association (TenneSEIA).

Deke Welling is Head of Project Development and Fulfillment Services at Correlate Inc. He has over 19 years’ experience in the energy industry with an emphasis on renewables and energy efficiency over the past seven years. Prior to entering the renewables sector, Mr. Welling was the CEO of Welling Resources, an energy development company focused on the exploration of oil and natural gas reserves in the U.S. It was this experience that led him into the renewables sector and leading a charge for more sustainable resources. Additionally, Mr. Welling also served as the CEO of Circle L Solar Inc., a top 100 solar installer in the United States since 2016. Through his leadership, Circle L Solar experienced a growth rate of over 2,250% from 2016 to 2019, resulting in his company being listed on the Inc. 5000 list of the fastest growing private companies in the U.S. (Rank #176) and being named ‘Top Energy Company’ and ‘Entrepreneur of Year for the Energy Industry’ by the American Business Awards® in 2019 and again for ‘Entrepreneur of the Year’ in 2021.

Kevin Warren is Head of Construction and Development Engineering at Correlate Inc. He is a solar veteran with over 12 years of experience in the field. Prior to co-founding CLS, Mr. Warren was the owner of Beacon Consulting and has originated, consulted, designed and/or engineered over 122 MW of PV installations ranging from small commercial to utility scale projects throughout Texas, California, Colorado and North Carolina. He holds a Photovoltaic Technical Sales Professional Certification from the North American Board of Certified Energy Practitioners and certifications from Solar Energy International in PV Installation, PV Technical Sales, PV battery-based design, PV design and engineering, and PV operations and maintenance. Along with PV expertise, Mr. Warren is a LEED Green Building Associate, a certified building analyst from the Building Performance Institute, a Certified Renewable Energy Professional from the Association of Energy Engineers and holds a designation in High-Performance Sustainable Buildings from the BOMI Institute. He studied Electrical Engineering at the University of Texas at Arlington.

Tom Kunhardt is Director of Customer Success at Correlate. He previously held a similar position at Clean.Tech and was Corporate Trainer, Learning & Development, at NRG Energy. He has 15 years of experience in the solar and clean energy industries helping homeowners and businesses find solutions to their energy needs. He holds a bachelor’s degree from the University of Massachusetts.

Correlate Infrastructure Partners Inc. (OTCQB: CIPI), closed Friday's trading session at $1.6, even for the day, on 90 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.32/$3.25.

Recent News

Reklaim Ltd. (TSX.V: MYID) (OTCQB: MYIDF)

The QualityStocks Daily Newsletter would like to spotlight Reklaim Ltd. (TSX.V: MYID) (OTCQB: MYIDF) .

Reklaim (TSX.V: MYID) (OTCQB: MYIDF) is the destination for consumers to access and reclaim their data. “Reklaim’s creation was a by-product of the ongoing evolution of data privacy and its impact on consumers and companies. The company’s revolutionary system allows consumers to log in to their platform and confirm their identity, unlocking data collected on them that has been bought and sold for years without their explicit consent. At that point, consumers can take control of their data and, if they choose, receive compensation for its use. With consent secured, Reklaim offers the data to Fortune 500 brands, platforms and data companies, and when sold, the consumer is compensated a fractional share of the revenue,” explains a recent article. “Seeking to capitalize on the increased global emphasis on data privacy, the desire from consumers to monetize their personal information, as well as growing commercial demands to access consumer-generated insights, Reklaim recently revealed that it had entered a non-binding letter of intent to purchase the assets of U.S.-based data broker, Multimedia Lists (‘MML’). The transaction, which is expected to double the revenue of the amalgamated entity post-acquisition immediately, will entail a purchase price determined as a multiple of MML’s EBITDA and will also include a performance earn-out over a four-year term.” To view the full article, visit

Reklaim Ltd. (TSX.V: MYID) (OTCQB: MYIDF) offers a privacy-compliant identity ecosystem both online ( and via a mobile app on iOS and Android in the U.S and Canada. Reklaim believes that consumers own their data and, consequently, have the right to access their online data and choose how it is used, whether for compensation or privacy. Reklaim gives consumers visibility regarding how their data is collected and compensates them for its use, all while also providing advertisers and brands with a source of data compliant with emerging privacy regulations.

The company is driven by the evolution of privacy and how it impacts consumers and companies. Reklaim sells compliant, zero-party data to Fortune 500 brands, platforms, and data companies so that they can offset the risk of non-compliance. ‘Zero-party data’ is data that a consumer proactively and intentionally shares with an organization. This contrasts with ‘third-party data,’ which organizations have collected unbeknownst to consumers for more than 20 years. Zero-party data is the most valuable data in the US$200B data market, as it provides organizations with explicit consumer opt-in vs. through an intermediary such as a data broker.

Reklaim empowers consumers to take back control of their data. The company allows consumers to visit the platform, confirm their identity, and uncover their data that has been collected and sold for years without their explicit consent. Consumers can add, edit or delete data that is associated with their profile and choose which pieces of data they would be willing to share for weekly compensation. Reklaim is the only company in the world today providing consumers with both access to their data that is circulating in the market and a guaranteed weekly paycheck. Alternatively, for users who do not want to sell their data, users can choose to protect their data and subscribe to a suite of subscription-based (SaaS) privacy tools that obfuscate the location of their device when browsing on a mobile phone and alert them when a third-party source has leaked their data or passwords.

Reklaim was founded in 2018 and is based in New York, with offices in Toronto.

Business Model

Reklaim’s primary revenue-generating operations stem from selling consented consumer data to companies and resellers that need data that is compliant with all applicable consumer privacy laws and regulations, including the California Consumer Privacy Act (CCPA). Major Fortune 500 customers and enterprise data platforms have validated Reklaim’s zero-party data and have added this data to their marketplaces and decision-making. Reklaim has sales across three core verticals: brands and agencies that buy advertising, platforms that sell data to Fortune 500 clients, and companies whose primary business is selling data to business customers.

  • Companies & Agencies that Buy Advertising – These customers use Reklaim’s compliant data to inform their media decisions in social, connected television, programmatic and other verticals. Sales cycles are short at about 30 days. Reklaim customers in this segment are Microsoft, Amgen, Bayer, UPS, and Hasbro, to name a few.
  • Platforms that Sell Data – Reklaim has integrated its zero-party data into 15 of the largest enterprise data platforms in the world. These platforms act as the ‘grocery stores’ of data, where the Fortune 500 come to make their data purchases. Reklaim’s data has been validated and added to these platforms, providing ubiquitous distribution of Reklaim data across the data ecosystem. Due to data quality verification and technical requirements, sales cycles are typically longer, about 60-90 days. Customers include LiveRamp, Transunion, Google, The Trade Desk, Lotame, and T-Mobile.
  • Data Companies that Sell Data – These customers need to purchase compliant data to continue offering data to their clients. Sales cycles often last 90-120 days, but these contracts are typically annual, have the highest value, and auto-renew. An example is Nielsen, the television measurement company.

Market Outlook

The data industry, valued at $245 billion in the U.S. and more than $400 billion globally, is being disrupted, and Reklaim is positioned to benefit from the destructive shift.

The disruption is driven by two factors: (1) technology is reducing access to core data that the industry has become dependent upon, and (2) government intervention is emerging through laws and regulations intended to protect consumer data privacy.

Over the past 20 years, the data industry has harvested and exploited consumer data without consumers’ express consent. However, the legal and regulatory environment surrounding consumer data acquisition is rapidly evolving, placing the consumer at the center of emerging privacy policies.

The European Union’s General Data Protection Regulation (GDPR) was rolled out in 2019, followed shortly by the CCPA and the California Privacy Rights Act. More recently, the Canadian Privacy Protection Act, Brazil’s General Data Protection Law, India’s Information Technology Act, and South Africa’s Protection of Personal Information have continued the trend. As a result, industries and companies currently relying on unconsented consumer data will experience a regulation-driven disruptive migration, forcing them sooner rather than later to use only fully consented data sources. This consumer data environment is driving companies to Reklaim to replace their current data providers.

While privacy policies continue to iterate to include the consumer, Big Tech, namely Apple and Google, are increasingly removing data from the market that brands and companies have relied on. Apple’s introduction of Advanced Ad Tracing (ATT) has impacted companies’ ability to track consumer behavior across applications. Facebook, in Q4 2021, was forced to accept a US$10B write down on revenue projections due to this change and is expecting a similar US$10B right down again in 2022.

Google is making similar changes, the most significant being the removal of the third-party cookie from its Chrome browser, which has a 65% market share. This third-party cookie is responsible for the tracking that websites use to monetize by tracking consumers. The removal of the Chrome cookie will put the 1.8 billion websites operating in the open web today under pressure to find a solution to replace the 65% loss in revenue.

Management Team

Neil Sweeney is Chairman and CEO of Reklaim. He has more than 20 years in the industry, with an established reputation for visionary entrepreneurship and an ability to develop technologies. Technologies Sweeney created are used by Fortune 500 brands like Coca-Cola, Lowe’s, Walmart, General Motors, Unilever, and Mondelez. They are the core component of top media demand-side platforms, including Adelphic, The Trade Desk, AppNexus, MediaMath, and Triton Media. He is a two-time finalist for Ernst & Young’s ‘Entrepreneur of the Year’ and received Deloitte’s ‘Fast 50’ award for three consecutive years for the growth of organizations he created.

Ira Levy is CFO at Reklaim. He has over 15 years of experience in a wide range of high-growth, early-stage public and private companies. Most recently, he held the roles of Corporate Controller at VIVO Cannabis Inc. (TSX: VIVO) and Senior VP/Head of Finance for start-up Honest Inc. (d/b/a Province Brands of Canada). He has also acted as an advisor for startup AI companies through the Creative Destruction Lab Program. He received his MBA in Accounting and Finance from the Schulich School of Business at York University and is a Chartered Professional Accountant.

Jake Phillips is Chief Technical Officer at Reklaim. He is a proven technology leader who excels at bridging the gap between innovation and business in dynamic environments. He has gained a breadth of industry knowledge across telco/cable, banking, and client services. His professional experience spans enterprise integration, mobility, big data, cloud operations, and data security.

Reklaim Ltd. (TSX.V: MYID) (OTCQB: MYIDF), closed Friday's trading session at $0.037915, even for the day. The average volume for the last 3 months is and the stock's 52-week low/high is $0.031/$0.3859.

Recent News

Silo Pharma Inc. (OTCQB: SILO)

The QualityStocks Daily Newsletter would like to spotlight Silo Pharma Inc. (OTCQB: SILO).

Silo recently extended Columbia University agreement to continue research for novel therapeutics to treat Alzheimer’s disease and stress-induced anxiety disorder

Preclinical studies demonstrate Silo’s jointly-developed Z-pod(TM) delivery technology holds and distributes therapeutics in a time-released manner to potentially provide targeted delivery

Additional treatment research includes funding for the UCSF Translational Psychedelic Program to study effects of psilocybin on various inflammatory conditions

Silo Pharma (NASDAQ: SILO) , a developmental stage biopharmaceutical company, fuses traditional therapeutics with psychedelic medicine to treat numerous underserved conditions, including fibromyalgia, post-traumatic stress disorder, and Alzheimer’s disease. Through a joint partnership agreement with Columbia University, researchers are currently evaluating the company’s novel therapeutic, designated as SPC-14.

Silo Pharma Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company, is focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as post-traumatic stress disorder (PTSD), fibromyalgia, Alzheimer’s disease, Parkinson’s disease, and other rare neurological disorders. Silo’s mission is to identify assets to license and fund research that the company believes will be transformative to the wellbeing of patients and the health care industry.

Silo is committed to developing innovative solutions to address a variety of underserved conditions. Combining Silo’s resources with world-class medical research partners, the company looks to make significant advances in the medical and psychedelic space.

Silo works to identify and partner with leading medical universities, providing the needed financial resources to develop safe therapeutic treatments while moving cutting-edge research through the clinical stage and into commercialization. The company is well-capitalized with access to additional funds as opportunities present themselves.

Silo recently engaged Donohoe Advisory Associates LLC for consulting and advisory services in connection with the potential uplisting of Silo’s common shares to the Nasdaq Stock Market.


Silo has entered into research agreements and partnerships with multiple leading medical universities.

The company is involved in a sponsored study with Maastricht University utilizing repeated low doses of ketamine and psilocybin to examine the effects on cognitive and emotional dysfunctions in Parkinson’s disease and to understand its mechanism of action. The investigator in the Netherlands is acquiring the substances for the study and will then finalize the documentation to submit to the ethics committee.

Additionally, in June 2021, Silo announced its entry into a scientific research agreement with the University of California San Francisco (UCSF). The agreement will leverage four other clinical trials being planned by the university to determine the effects of psilocybin on inflammation. The study will take place at The Translational Psychedelic Research (TrPR) Program at UCSF.

Silo also recently extended its exclusive option agreement with the University of Maryland, Baltimore (UMB) to explore a novel invention generally known as joint-homing peptides. These peptides are being developed for use in the investigation and treatment of arthritogenic processes and can be used for enhanced targeting of therapeutic agents.

This agreement includes the study of two separate peptides. The first is an option and study for the treatment of arthritis. The second is a patented licensed peptide for the central nervous system, with an initial study for MS autoimmune diseases, in addition to rheumatoid arthritis. Animal studies are underway for both initial indications relating to the UMB agreement, with the potential for studies evaluating additional indications in the future.

Finally, Silo signed an agreement with Columbia University granting it an option to license certain assets currently under development, including an Alzheimer’s disease formulation targeting NDMARs and 5-HT4Rs, as well as a prophylactic treatment for stress-induced disorders and PTSD. Both candidates are currently being tested in mice and have already provided early data.

In addition to its university partnerships, Silo entered a joint venture agreement with Zylo Therapeutics Inc. (“ZTI”) focused on the development of ketamine and psilocybin using ZTI’s Z-Pod™ technology for the transdermal time released delivery of therapeutics. In November 2021, the company announced ZTI’s reception of its first ketamine shipment and initiation of loading ketamine into its Z-Pod technology. In a news release, Eric Weisblum, CEO of Silo, called the development an “important milestone” that will help the company “study the benefits of slow-release transdermal release of Ketamine.”

Market Overview

According to Coherent Market Insights, the fibromyalgia treatment market was valued at $2.78 billion in 2018 and has a projected CAGR of 3.3% over the forecast period 2018 to 2026. Fibromyalgia is a condition that causes pain all over the body, sleep problems, fatigue, and emotional and mental distress.

The global PTSD therapeutics market is expected to reach $10.68 billion by 2026 with a CAGR of 4.5% during the forecast period from 2018 to 2026, according to a report by Credence Research. Growing prevalence of PTSD is the chief factor driving the global treatment market. Increases in events such as wars, combat, and interpersonal violence has been a major contributing factor. Other factors like growing emphasis on rehabilitation initiatives by governments for treating their war veterans has also been facilitating the increase in demand for PTSD therapeutics.

Fortune Business Insights reports the global Parkinson’s disease treatment market is predicted to grow to $8.38 billion by 2026, with a CAGR of 8.1% during the forecast period. Parkinson’s is a neurodegenerative disease of the central nervous system which primarily affects the brain, causing uncontrollable shaking and tremors, difficulties in balance and restricted body movement making it difficult for the person to function or perform a daily routine.

Management Team

Eric Weisblum is CEO and founder of Silo Pharma. He has over 25 years of Wall Street experience, most recently in the biotechnology sector. He has served on the board of Aikido Pharma and was the president of Sableridge Capital. He has a proven track record in licensing therapeutic assets and assisting in their development. He brings to the company nearly 20 years of expertise in structuring and trading financial instruments. He holds a bachelor’s degree from the University of Hartford’s Barney School of Business.

Dr. Kevin Muñoz was appointed to the Silo board of directors in November 2020. He teaches biomedical sciences and medical intervention for the Passaic County Technical Institute. He previously served as Director of Operations at Physical Medicine and Rehabilitation. He began his career with Harlem Health Promotion Center in New York City as a research assistant. He earned a bachelor’s degree from the University of Michigan and a Doctor of Medicine from Xavier University School of Medicine.

Josh Woolley, M.D., Ph.D., is a Scientific Advisor for Silo. He is an associate professor in the Department of Psychiatry and Behavioral Sciences at the University of California, San Francisco. He is also a psychiatrist on staff at the San Francisco Veterans Affairs Medical Center. He is the director and founder of the Bonding and Attunement in Neuropsychiatric Disorders Laboratory. He received both his M.D. and his Ph.D. in Neuroscience from UCSF, where he completed his psychiatry residency training.

Charles Nemeroff, M.D., Ph.D., is a Scientific Advisor for Silo Pharma. He directs the Institute for Early Life Adversity Research within the Department of Psychiatry and Behavioral Sciences as part of the Mulva Clinic for the Neurosciences. He was chair of the Department of Psychiatry and Behavioral Sciences and clinical director of the Center on Aging at the University of Miami Miller School of Medicine. He received his M.D. and Ph.D. in neurobiology from the University of North Carolina School of Medicine.

Silo Pharma Inc. (OTCQB: SILO), closed Friday's trading session at $3.75, off by 3.8757%, on 10,090 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $3.52/$12.445.

Recent News

Lexaria Bioscience Corp. (NASDAQ: LEXX)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (NASDAQ: LEXX).

The CDC reported more than 670,000 annual deaths in the United States with high blood pressure as a primary or contributing cause

Lexaria’s patented DehydraTECH(TM) technology has been shown, through HYPER-H21-4 study, to decrease high blood pressure in subjects through DehydraTECH-CBD-enabled dosing

The global antihypertension drug market was valued at over $22.5 billion in revenue in 2018 and is expected to grow at a CAGR of 3.1%, resulting in a market of over $28.7 billion by 2026

In the United States, uncontrolled high blood pressure is common among adults – with only one in four having the condition under control. According to the Centers for Disease Control and Prevention (“CDC”), in 2020, more than 670,000 deaths in the United States had high blood pressure as a primary or contributing cause ( ). Lexaria Bioscience (NASDAQ: LEXX) , a global innovator in drug delivery platforms, has announced that its human clinical study HYPER-H21-4 may be the world's first study to evidence a sustained drop in blood pressure in normally active patients following multiple weeks of oral cannabidiol (“CBD”) therapy using the company's patented DehydraTECH(TM)-enabled CBD capsule formulation.

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator in drug delivery platforms. The company’s patented technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules. DehydraTECH promotes fast-acting, less expensive and more effective oral drug delivery and has been thoroughly evaluated through in vivo, in vitro and human clinical testing.

DehydraTECH is covered by 21 issued and more than 50 pending patents in over 40 countries around the world. Lexaria’s first patent was issued by the U.S. Patent and Trademark Office in November 2016 (US 9,474,725 B1), providing 20 years of patent protection expiring June 2034. Multiple patents have been awarded since then and are expected in the future.

Lexaria has a collaborative research agreement with the National Research Council (NRC), the Canadian government’s premier research and technology organization. The company has filed for patent protection for specific delivery of nicotine, vitamins, NSAIDs, testosterone, estrogen, cannabinoids, terpenes, PDE5 inhibitors (with brand names like Viagra), tobacco and more.

Lexaria began developing DehydraTECH in 2014 and has since continued to strengthen and broaden the technology. The company has no plans to create or sell Lexaria-branded products containing controlled substances. Instead, Lexaria licenses its technology to other companies around the world to offer consumers the best possible performance across an array of ingestible product formats.

The company’s technology is best thought of as an additional layer that providers of consumer supplements, prescription and non-prescription drugs, nicotine and CBD products can utilize to improve the effectiveness of their own existing or planned new offerings. Lexaria has licensed DehydraTECH to multiple companies, including a world-leading tobacco producer for the research and development of smokeless, oral-based nicotine products, and for use in industries that produce cannabinoid beverages, edibles and oral products.

DehydraTECH is suitable for use with a wide range of product formats including pharmaceuticals, nutraceuticals, consumer packaged goods and over-the-counter capsules, pills, tablets and oral suspensions.

DehydraTECH Technology

Lexaria’s DehydraTECH is designed specifically for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients. DehydraTECH increases their effectiveness and improves the way active pharmaceutical ingredients enter the bloodstream. The major benefits to a subject ingesting a DehydraTECH-enabled drug or consumer product can be summarized by the following:

  • Speeds up delivery – the effects of the product are felt by the subject in just minutes.
  • Increases bioavailability – the technology is much more effective at delivering a drug or product into the bloodstream.
  • Increases brain absorption – animal testing suggests significant improvement in the quantity of drug delivered across the blood-brain barrier.
  • Improves drug potency – more of the ingested product is made available to the body, so lower doses are required to achieve the desired effect.
  • Reduces drug administration cost – lower doses mean lower overall drug costs.
  • Masks unwanted taste – the technology eliminates or reduces the need for sweeteners.

Lexaria has demonstrated in animal studies a propensity for DehydraTECH technology to elevate the quantity of drug delivered across the blood-brain barrier by as much as 1,900 percent, initiating additional new patent applications and opening possibilities for improved drug delivery.

Since 2016, DehydraTECH has repeatedly demonstrated, with cannabinoids and nicotine, the ability to increase bio-absorption by up to five to 10 times, reduce time of onset from one to two hours to just minutes, and mask unwanted tastes. The technology is to be further evaluated for additional orally administered bioactive molecules, including antivirals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) and nicotine.

Market Outlook

Lexaria’s ongoing research and development efforts are mainly focused on development of product candidates across several key segments:

  • Oral Cannabinoids – a market estimated to be worth $18.4 billion in 2021 and expected to reach $46.2 billion by 2025.
  • Antivirals – an estimated $52.1 billion market in 2021 that’s expected to grow to $66.7 billion by 2025.
  • Oral Mucosal Nicotine – smokeless tobacco products, a $13.6 billion market in 2018, is forecast to grow at 7.2 percent annually through 2025.
  • Human Hormones – estrogen and testosterone replacement therapies represented a $21.9 billion market in 2019, with a forecast CAGR of 7.7 percent through 2027.
  • Ibuprofen and Naproxen – NSAID sales totaled $15.6 billion globally in 2019 and are projected to reach $24.4 billion by 2027.
  • Vitamin D3 – the global market size was $1.1 billion in 2021, growing at 7 percent per year and expected to reach $1.7 billion in 2026.

Management Team

Chris Bunka is Chairman and CEO of Lexaria Bioscience Corp. He is a serial entrepreneur who has been involved in several private and public companies since the late 1980s. He has extensive experience in the capital markets, corporate governance, mergers and acquisitions, as well as corporate finance. He is named as an inventor on multiple patent innovations.

John Docherty, M.Sc., is the President of Lexaria. He is a pharmacologist and toxicologist, and a specialist in the development of drug delivery technologies. He is the former president and COO of Helix BioPharma Corp. (TSX: HBP). He is named as an inventor on multiple issued and pending patents.

Greg Downey is Lexaria’s CFO. He has more than 35 years of diverse financial experience in the mining, oil and gas, manufacturing, and construction industries, and in the public sector. He served for eight years as CFO for several public companies and has provided business advisory and financial accounting services to many large organizations.

Gregg Smith is a strategic advisor to Lexaria. He is a founder and private investor with Evolution VC Partners. He is a member of the Sand Hill Angels and held previous investment banking roles with Cowen and Company and Bank of America Merrill Lynch.

Dr. Philip Ainslie serves as a scientific and medical advisor to Lexaria. He is co-director for the Centre for Heart, Lung and Vascular Health, Canada. He is also Research Chair in Cerebrovascular Physiology and Professor at the School of Health and Exercise Sciences, Faculty of Health and Social Development at the University of British Columbia.

Lexaria Bioscience Corp. (LEXX), closed Friday's trading session at $2.1735, off by 1.8736%, on 1,924 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $1.80/$6.72.

Recent News

Flora Growth Corp. (NASDAQ: FLGC)

The QualityStocks Daily Newsletter would like to spotlight Flora Growth Corp. (NASDAQ: FLGC).

Flora Growth Corp. (NASDAQ: FLGC) is a cannabis cultivator, brand manufacturer and global distributor. “The Canadian company with a productive base of operations in Colombia’s fertile greenbelt is licensed to cultivate cannabis on a 100-hectare (about 247-acre) farming facility and then deliver its product to its GMP-certified processing facility in the nation’s capital, where beauty, phytotherapeutic and nutraceutical products are prepared for market…. Flora’s brand division is focused on developing plant-based consumer products, such as cannabinoid-infused juices, gummies, topicals, inhalables, and skin care. But the company also prioritizes the manufacture of ‘cannabinoid-derived medical formulations that can be sold domestically and internationally,’” a recent article reads. “In September, the company announced that it had completed its first exports of high-CBD dried cannabis flower to Switzerland and the Czech Republic and CBD isolate to the United States. ‘We are proud to help increase access to safe, legal CBD and THC to consumers all over the globe. We look forward to working closely with our partners in Europe and North America to bring high-quality Colombian cannabis and raw materials to market,’ Flora Growth Chairman and CEO Luis Merchan stated at the time.” To view the full article, visit

Flora Growth Corp. (NASDAQ: FLGC) is an internationally focused cannabis brand builder that leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its diverse business divisions, including cosmetics, hemp textiles, and food and beverage. Flora Growth operates one of the largest outdoor cultivation facilities in the world with an aim of marketing a higher-quality premium product at below-market prices. By prioritizing natural ingredients and value-chain sustainability across its portfolio, the company creates premium products that help consumers restore and thrive.

Flora Growth completed the first traditional cannabis IPO on Nasdaq in May 2021. Although currently headquartered in Toronto, Ontario, with plans to relocate its head office to Miami, Florida, the company’s base of operations is in Colombia, where it has built an extensive distribution network that includes Colombia’s largest distributors.

Currently, Flora Growth is organically growing market share for its existing brand portfolio (pharmaceuticals, textiles, cosmetics, and food & beverage) while seeking revenue-generating acquisitions that offer an accretive distribution network to amplify revenue growth.

Existing Brand & Product Portfolio

Flora Growth’s portfolio spans a number of verticals – each with a thoughtful brand designed to resonate with its intended end consumer. In line with the company’s mission, each brand prioritizes natural ingredients and value-chain sustainability.

Flora Lab S.A.S

Flora Lab is the company’s GMP certified manufacturing and R&D center focused on producing pharmaceuticals, cosmetics, and nutraceuticals for domestic and international markets. Its offerings include product lines that are private label, white-label, and custom formulas.

Through Flora Lab, Flora Growth has relationships with 1,500+ distribution channels, manufactures 63+ OTC products registered with INVIMA (Colombia National Food and Drug Surveillance Institute), and holds multiple GMP certifications enabling international export in an effort to leverage Flora Lab’s capacity to produce a wide range of CBD-infused products.

Flora Beauty

Flora Beauty is the company’s CBD beauty and cosmetics division founded by fashion and beauty industry icon Paulina Vega. Its current offerings include two CBD skincare brands targeting the U.S. and Latin American markets – MIND NATURALS and AWE. These lines exemplify Flora Growth’s socially conscious approach to business.

Currently, Flora Beauty products are offered globally through e-commerce, as well as through Falabella’s 111 retail locations across Latin America. The company is in negotiations with major department stores to launch the line in the U.S. and is also exploring opportunities in the U.K. and other European markets.

KASA Wholefoods

KASA Wholefoods is a Colombian manufacturer of food and beverages leveraging responsibly sourced exotic fruits from the Amazon. KASA has a $10 million+ distribution agreement with Tropi, Colombia’s largest food distributor, which has 130,000+ distribution points across the country.

Mambe, KASA’s leading brand, is already offered through over 980 distribution points across Colombia. Flora Growth expects this network to grow to over 1,200 distribution points in 2021, including one of Colombia’s largest coffee chains, Tostao Café & Pan.

Hemp Textiles & Co.

Through its Hemp Textiles division, Flora Growth intends to utilize its large land package and cultivation infrastructure to capture market share in the rapidly growing hemp industrials segment.

The company’s first brand through this division, Stardog Loungewear, offers a line of comfortable loungewear made from natural, organic materials. Stardog has been distributing globally through e-commerce and brick and mortar channels in Bogota since fall 2020, and the company intends to open U.S. brick and mortar locations in 2021.

Accretive M&A

Flora Growth is targeting transactions to complete the supply chain via key infrastructure to enhance its global distribution with the aim to compete on low-cost, high-quality inputs paired with premium brands that create business lines with robust margins.

To date, Flora has announced two major transactions.

Koch & Gsell (Acquisition)

  • Amplify CPG portfolio’s revenue growth through leading brand, Heimat, currently with TTM revenues of $7.6 million.
  • Leverage Koch &Gsell’s distribution network of 2,500+ stores to introduce Flora to the Swiss, European and Asian markets.
  • Bring patented hemp cigarette manufacturing technology into new markets utilizing Flora’s high-quality cannabis.

Hoshi International (Investment)

  • Equity Investment of €2 million into Hoshi to establish Flora as a preferred supplier to two EU processing facilities.
  • Opens gateway for Flora Growth’s cannabis through international distribution agreements in the EU and U.K.
  • Hoshi’s experienced team and increased access to the EU cannabis market to serve as a catalyst for revenue growth.


Key to Flora Growth’s expansion efforts is its cultivation strategy. The company’s Cosechemos farm, located in Bucaramanga, Colombia, is currently licensed to cultivate 247 acres of cannabis. Through three successful pilot crop plantings, the location has demonstrated a production cost of just $0.06/gram. For comparison, the average cost of North American cannabis (based on 2019 figures from Aphria, Tilray, Sundial, and Aurora) equates to roughly $1.89/gram.
Flora Growth is uniquely positioned to capitalize on Colombia’s favorable growing conditions, low-cost infrastructure, and affordable local workforce as it looks to ramp up its cultivation efforts moving forward.

Leadership Team

Bernard Wilson is the Chairman of Flora Growth. A senior financial professional, Dr. Wilson is the former Vice-Chairman of PricewaterhouseCoopers LLP and is the Chairman of the Founders Board of the Institute of Corporate Directors. He has also served as Chairman of the Canadian Chamber of Commerce; Chairman of the International Chamber of Commerce – Canada; and Member of the Canada/U.S. Trade Committee. Dr. Wilson draws on this experience to ensure Flora Growth adheres to effective corporate governance practices.

Luis Merchan is the company’s President and CEO. He is a proven executive with over a decade of experience in enterprise sales management, corporate strategy, merchandising and expense management, and customer experience. Mr. Merchan previously served as Macy’s Inc.’s Vice President of Workforce Strategy and Operations, where he managed the enterprise’s multi-billion-dollar P&L expense line for the entire 540 store portfolio. Throughout his tenure at Macy’s, he led various sales and marketing initiatives, including the B2B corporate sales team that was responsible for $160 million in annual revenue. Mr. Merchan obtained his Bachelor of Industrial Engineering from Pontifical Xaverian University in Bogota, Colombia, and his MBA from McNeese State University. He also holds a Graduate Certificate in Marketing Management from Harvard.

Juan Manuel Galan is a Strategic Advisor to the Flora Growth management team. Mr. Galan currently serves as a senior consultant to The World Bank. He is a politician and former senator of Colombia, serving three terms from 2006 to 2018 as a member of the Colombian Liberal Party. He is also a former professor at the University of Rosario and holds more than 20 years of journalistic, academic, governmental and parliamentary experience. During his time as a senator, Mr. Galan was a key leader, with 29 bills and 27 debates on political control, and 17 laws to his name. The most relevant of those laws was authoring the medical cannabis law that resulted in the legalization of medical cannabis in Colombia.

Stan Bharti is a Director of Flora Growth. Mr. Bharti currently serves as Executive Chairman of Forbes & Manhattan. He has more than 30 years of professional experience in business, finance, markets, operations and more, with a focus on the resource and technology sectors. To date, Mr. Bharti has amassed over $3 billion worth of investment capital for the companies with which he has worked and their shareholders. He is a Professional Mining Engineer and holds a master’s degree in engineering from Moscow, Russia, and University of London, England.

Javier Franco is the company’s VP of Agriculture. Mr. Franco is a master horticulturist with more than 25 years of experience in the design, implementation, and management of cultivation and propagation facilities of more than 30 species of cut flowers in Latin America. He completed his agricultural studies at Zamorano University in Honduras and later at an International Exchange Program at Ohio State University. Mr. Franco has directed technical, commercial, and research groups in the cut flower, fruit and vegetable markets in Latin America and has participated in the commercial development of new technologies applied in agribusiness. He has also led the agri-management of organic crops and certifications of Good Agricultural Practices.

Flora Growth Corp. (FLGC), closed Friday's trading session at $0.52, off by 4.9186%, on 536,384 volume. The average volume for the last 3 months is 530,724 and the stock's 52-week low/high is $0.5011/$5.6092.

Recent News

Advanced Container Technologies Inc. (OTC: ACTX)

The QualityStocks Daily Newsletter would like to spotlight Advanced Container Technologies Inc. (OTC: ACTX).

Before states began legalizing cannabis in the late nineties and early 2000s, the plant had been prohibited across the country for decades. Over the years, tens of thousands of Americans were convicted and imprisoned over cannabis-related charges, with a majority of them being people of color. Even though dozens of states now allow medical and recreational cannabis use, plenty of people are still held back from fully participating in life by cannabis offenses on their records. Hundreds of thousands of people have been arrested for cannabis-related offenses in the past couple of years and cannabis arrests overall make up more than half of all drug arrests across the country. Amidst the landscape of patchwork state cannabis policies and federal prohibition, the U.S. Sentencing Commission (USSC) has revealed that it is considering making amendments to sentencing guidelines on past cannabis use. The industry needs the prohibitionist system to be overhauled. Only then will allied industry actors like Advanced Container Technologies Inc. (OTC: ACTX) be free from improperly being lumped together with companies that deal in marijuana directly.

Advanced Container Technologies Inc. (OTC: ACTX) is in the business of selling and distributing self-contained, automated, indoor “micro-farms” called Grow Pods, along with related equipment and supplies. Additionally, the company designs and sells patented proprietary medical-grade plastic containers, known as the Medtainer®, that store and grind pharmaceuticals, herbs, teas and other solids or liquids.

ACTX is the leading distributor of Grow Pods. With a controlled environment, food and herbs can be grown without pesticides, harmful chemicals or risk of pathogen contamination, and with low energy consumption. Restaurants, grocery stores, non-profits, MSOs and entrepreneurs can use Grow Pods to ensure a fresh supply of ultra-clean produce year-round.

The company entered the Grow Pod business in November 2020 with its acquisition of all shares of Advanced Container Technologies Inc., a California corporation. As of February 28, 2022, ACTX is exploring the acquisition of the assets and the assumption of some or all of the liabilities of GP Solutions Inc., the developer and manufacturer of Grow Pods, for which ACTX is currently the sole U.S. distributor.

Because Grow Pods can be located almost anywhere, produce can be grown closer to the point of consumption and harvested at its peak, providing nutritious fruits and vegetables where needed. Indoor micro-farms, utilizing a practice known as vertical farming, have attracted the attention of governments and universities, which are now promoting vertical farming as a way to combat food insecurity and inequities.

The United States Department of Agriculture (USDA) has stated that vertical farming “is no longer a futuristic concept.” The department is enthusiastic about vertical farming, particularly those utilizing repurposed shipping containers, such as Grow Pods. Arizona State University reports that vertical farming reduces water use by 90 percent compared to conventional farming but produces 10 times the crop yield.


Grow Pods

One of the company’s main business units is focused on selling advanced, self-contained hydroponic containers called Grow Pods. These unique and innovative automated systems are essentially micro-farms that can be placed virtually anywhere and, with their controlled and specially filtered environment, allow cultivation of a wide variety of crops, 365 days a year. The Grow Pod controlled environment offers major advantages for the production of high-value crops. The ability to grow year-round and the ability to cultivate in a smaller footprint using less water and power are some of the primary advantages of the system. Grow Pods offer constant temperature, humidity and airflow control, as well as automated watering and lighting schedules for optimal growth and minimal labor requirements, regardless of crop.


ACTX meets the needs of the pharmaceutical and medical markets, including the cannabis and hemp industries, with patented packaging systems. The company designs, customizes, brands and sells proprietary medical grade plastic containers that can store pharmaceuticals, herbs, teas and other solids or liquids, with a special built-in feature that can grind solids and shred herbs. The company’s flagship container product is the patented Medtainer®, a child resistant, medical-grade herb container and grinder that is water-tight, air-tight and smell proof. Packaging in the cannabis industry is critical, with numerous stringent regulations about how cannabis products must be packaged and labeled. ACTX also offers custom-branded, compliant vacuum seal bags and other retail container solutions.

Equipment and Supplies

ACTX markets and sells two principal products: Grow Pods, which are specially modified insulated shipping containers manufactured by GP Solutions Inc., in which plants, herbs and spices may be grown hydroponically in a controlled environment, and Medtainers®, which may be used to store pharmaceuticals, herbs, teas and other solids or liquids and can grind solids and shred herbs. The company also markets and sells various products related to Grow Pods and the Medtainer®, as well as providing private labeling and branding services for purchasers of Medtainers® and certain related products.

GP Solutions manufactures and sells other products, such as humidity controllers and LED lighting systems for vertical farming. The company’s specially designed lighting panels are programmed to emit the exact wavelength of light that each crop requires. The system has a daybreak-to-nightfall feature that gives plants the proper chromatic signals to grow rapidly and fruitfully. High efficiency LED light strips supply the crops with a red and blue light spectrum required for photosynthesis in the spectrum that plants need most.

Market Overview

The global vertical farming market is expected to reach $33.02 billion by 2030, according to a new report by Grand View Research. The market is forecast to expand at a CAGR of 25.5 percent from 2022 to 2030, according to Grand View. Escalating production of biopharmaceutical products, including cannabis, is anticipated to drive the market. The building-based segment of the market is expected to register a significant CAGR of 27.8 percent over the projected period. In addition, the climate control segment is expected to see high growth.

The global cannabis packaging market is expected to reach $14.34 billion by 2028, according to analysis by Reports and Data. The analysis forecasts 1,700 percent growth in cannabis users by the end of 2026, with packaging likely observing a whopping 26.42 percent growth in the forecast period. There are significant barriers to entry in the cannabis packaging market, giving an advantage to companies already established in the sector. These barriers include developing a thorough knowledge of the myriad regulations that govern cannabis packaging (which differ in each state), and child-resistance requirements.

Management Team

Douglas P. Heldoorn is the Founder and Chairman of Advanced Container Technologies Inc. He also holds the positions of President, CEO and COO at the company. Mr. Heldoorn has served on the Board of Directors since its inception in 2013. He has also previously held the position of Executive General Manager at Nissan Motor Corp.

Jeffory A. Carlson is CFO and Treasurer of ACTX. Mr. Carlson has also served as the company’s Corporate Controller since 2014.

Advanced Container Technologies Inc. (OTC: ACTX), closed Friday's trading session at $0.45, off by 6.25%, on 7,568 volume. The average volume for the last 3 months is 7,568 and the stock's 52-week low/high is $0.2005/$1.87.

Recent News

Odyssey Group International Inc. (OTC: ODYY)

The QualityStocks Daily Newsletter would like to spotlight Odyssey Group International Inc. (OTC: ODYY).

Since the early 2000s, research on concussions has improved significantly. Concussions are traumatic brain injuries that affect the brain function of an individual. It is estimated that millions of Americans experience concussions annually, with a survey conducted by the CDC in 2017 finding that 2.5 million students in high school had experienced concussions in 2016. Of this figure, which represents about 15% of all students in high school in the country, at least 40% of those who experienced concussions were girls. While increasing awareness among the American public may have led to the greater numbers of teens reporting concussions, not much is known about these injuries. This is particularly true with regard to the differences between women and men. Various studies have suggested that girls and women may have a heightened risk of experiencing concussions and may also need more time to recover from these brain injuries. These differences will be discussed at the International Conference on Concussion in Sport. Experts on these injuries hope that the conference will help come up with a consensus statement that may improve research on how concussions affect women. There’s still a lot to learn about concussion, and one would be surprised to learn that not a single drug is currently approved by the FDA as a treatment for concussion. A number of companies, including Odyssey Health Inc. (OTC: ODYY), are undertaking drug-development programs to fill this unmet need so that patients can receive the clinical help they need.

Odyssey Group International Inc. (OTC: ODYY) is a medical technology company focused on developing lifesaving medical products that offer technological and clinical advantages over current standards of care.

The company’s portfolio of product technologies is diverse, featuring four unique medical products in development. Odyssey’s goal is to deliver superior products with enhanced clinical utility and market potential, thereby yielding a high rate of return for its shareholders and partners. It is guided by a senior management team with significant experience relating to refining technologies, building commercial systems and forging strategic partnerships.

Product Portfolio


Odyssey has two pharmaceutical products in development:

  • PRV-002 is a novel compound for the treatment of concussion, which currently has no FDA-approved drug. In pre-clinical studies, PRV-002 has been shown to significantly improve both neuroscore and memory score following injury in rats subjected to concussion models. Importantly, the first-in-class novel neurosteroid demonstrated no drug-related toxicity in these trials.
    • PRV-002 is currently being evaluated in a phase I clinical trial for the treatment of concussion, with phase II trials planned for launch in Fall 2022. Odyssey has also highlighted the potential of PRV-002 for additional indications such as Alzheimer’s disease, Parkinson’s disease, ALS and chromic traumatic encephalopathy (CTE).
  • PRV-001 is a novel compound intended to treat Niemann-Pick disease, a rare neurodegenerative-lysosomal storage disorder that affects an estimated 1 in 150,000 individuals in the U.S., demonstrating a 5x higher incidence in Middle Eastern populations.
    • Odyssey expects to receive Orphan Drug designation from the FDA for PRV-001, which would accelerate its pathway to FDA approval and provide seven years of market exclusivity.

Medical Devices

Odyssey is also developing two medical device candidates:

  • CardioMap® is intended to provide early, non-invasive testing for heart disease. The system offers a number of potential advantages over traditional EKGs, including requiring less training to operate, offering heightened sensitivity and coming in a small and portable form factor. CardioMap is being developed for a 510(k) regulatory pathway, which requires a study to demonstrate equivalence to legacy EKG offerings.
    • When approved, CardioMap is expected to be the only device in its class that has a predictive value, illustrating ‘grey’ areas where deterioration has begun but not yet led to pathology. Odyssey expects this feature to provide a powerful incentive for doctors to use the CardioMap device in end markets such as hospitals, doctors’ offices, rehabilitation centers and sports medicine practices.
  • Save-A-Life (SAL) is a patented, single-action, instantaneous, handheld, mechanical anti-choking device that creates a vacuum chamber in the mouth to dislodge throat obstructions in a matter of seconds, all without harm to the victim. The device is currently in development, with a proof of concept established.
    • Odyssey believes that, once FDA-approved, its anti-choking device will quickly become the “accepted” standard and leader in the treatment of choking incidents globally. Its low-cost manufacturing and convenient portable design give SAL a competitive edge over competing devices utilizing cumbersome masks.

Market Opportunities

Odyssey’s varied development pipeline positions it to address a number of sizable market opportunities with significant unmet medical need. Concussions alone currently account for medical costs of roughly $10-15 billion annually in the U.S., despite the lack of a currently approved FDA drug treatment. This need is particularly apparent in the military and sports industry, where the likelihood of athlete head-injury recurrence is estimated at 75%.

It is for this reason that, in March 2021, Odyssey announced the formation of a sports advisory board featuring well-known athletes supporting the company’s efforts to enhance public awareness of traumatic brain injuries and concussions, as well as the need for an FDA-approved therapy. Members of Odyssey’s sports advisory board include NFL Hall of Famers Kurt Warner & Brett Favre and two-time Olympic gold medalist Abby Wambach.

With its CardioMap platform, Odyssey is targeting the global cardiac monitoring market, which was valued at $28 billion in 2021 by Insight Partners and forecast to reach $43 billion by 2028.

Save-A-Life targets a similarly underserved market. Choking is the fourth-leading cause of death in children, and approximately 5,000 choking deaths occur each year in the U.S. While 95% of these deaths result from in-home incidents, current choking rescue devices fail to address in-home applications.

Management Team

Joseph Michael Redmond is the President, CEO and Chairman of Odyssey. He has over 30 years of commercial experience in medical device companies, previously serving as CEO of Parallax Health Sciences Inc., V.P. of Business Development for DxTech Inc. and V.P. of Sales and Marketing for Bioject Medical Technologies Inc. While at Bioject, Mr. Redmond helped raise over $15 million in capital, entered into several licensing and distribution deals with major biotech and pharmaceutical companies and grew the market cap of the company from under $10 million to over $400 million. He started his career at Abbott Labs and holds a B.A. from Denison University.

Christine M. Farrell is the company’s CFO and Secretary. Prior to joining Odyssey, Ms. Farrell was Vice President of Finance for Bioject Medical Technologies Inc. She also held accounting and financial management positions with Spar-Tek Industries, a manufacturer of high quality and cutting-edge technology for the plywood industry, and Action Machinery, a seller of new and used robotic machine tools and equipment. Ms. Farrell holds a B.A. in Accounting from the University of Washington and an M.B.A. from Willamette University.

Dr. Jacob W. Vanlandingham is Odyssey’s Head of Drug Development. Dr. Vanlandingham holds a Ph.D. in neuroscience with a molecular biology focus. He is a member of the Society for Neuroscience, American Society for Nutritional Sciences, National Neurotrauma Society, Faculty for Undergraduate Research in Neuroscience and the International Association of Medical Science Educators.

Odyssey Group International Inc. (OTC: ODYY), closed Friday's trading session at $0.225, off by 5.2233%, on 126,763 volume. The average volume for the last 3 months is 126,763 and the stock's 52-week low/high is $0.11/$0.64.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.